

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/059179 A1

- (51) International Patent Classification⁷: C12Q 1/68 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/US2004/041882
- (22) International Filing Date: 10 December 2004 (10.12.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/529,438 12 December 2003 (12.12.2003) US
- (71) Applicant (for all designated States except US): **BAYER PHARMACEUTICAL CORPORATION** [US/US]; 400 Morgan Lane, West Haven, CT 06516 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KASPER, James** [US/US]; 640 Evergreen Avenue, Hamden, CT 06518 (US). **PAULOSKI, Nicole** [US/US]; 14 Aceto Street, Branford, CT 06405 (US). **TAYLOR, Ian** [US/US]; 149 Country Way, Madison, CT 06443 (US). **ELTING, James** [US/US]; 5 Heatherwood Drive, Madison, CT 06443 (US). **SARR, Timothy** [US/US]; 104 West Street, A8, Rocky Hill, CT 06067 (US).
- (74) Agents: **GREENMAN, Jeffrey, M.** et al.; Bayer Corporation, 400 Morgan Lane, West Haven, CT 06516 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
 - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
 - of inventorship (Rule 4.17(iv)) for US only
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY

(57) Abstract: The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of stanniocalcin as a biomarker for VEGFR2 inhibitors.

WO 2005/059179 A1

**METHODS FOR PREDICTION AND PROGNOSIS OF CANCER,
AND MONITORING CANCER THERAPY**

[001] This application claims benefit of U.S. Provisional Application Serial No. 60/529,438, filed December 12, 2003, the contents of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[002] The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of stanniocalcin as a biomarker for Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) inhibitors.

BACKGROUND OF THE INVENTION

[003] Many disease states are characterized by differences in the expression levels of various genes either through changes in the copy number of the genetic DNA or through changes in levels of transcription of particular genes (e.g., through control of initiation, provision of RNA precursors, RNA processing, etc.). For example, losses and gains of genetic material play an important role in malignant transformation and progression. These gains and losses are thought to be driven by at least two kinds of genes, oncogenes and tumor suppressor genes. Oncogenes are positive regulators of tumorigenesis, while tumor suppressor genes are negative regulators of tumorigenesis (Marshall, Cell 64:313-326, 1991; Weinberg, Science 254:1138-1146, 1991). Therefore, one mechanism of activating unregulated growth is to increase the number of genes coding for oncogene proteins or to increase the level of expression of these oncogenes (e.g., in response to cellular or environmental changes), and another mechanism is to lose genetic material or to decrease the level of expression of genes that code for tumor suppressors. This model is supported by the losses and gains of genetic material associated with glioma progression (Mikkelsen, et al., J. Cellular Biochem. 46:3-8, 1991). Thus, changes in the expression (transcription) levels of particular genes (e.g., oncogenes or tumor suppressors) serve as signposts for the presence and progression of various cancers.

[004] Compounds which are used as therapeutics to treat these various diseases (e.g., cancer) presumably reverse some, or all, of these gene expression changes. The expression change of at least some of these genes may, therefore, be used as a method to monitor, or even predict, the efficacy of such therapeutics. As a result, some or all of these gene expression changes can be considered to be, and can be utilized as, a biomarker. By extension, the gene products can also be used as the biomarker. Besides being used to monitor or predict the efficacy of a therapeutic,

biomarkers might also be used to select patients who are predicted to respond positively to therapeutic administration and those that might revert to non-responsive status. The analysis of these expression changes may be performed in the target tissue of interest (e.g., tumor) or in some surrogate cell population (e.g., peripheral blood leukocytes). In the latter case, correlation of the gene expression changes with efficacy (e.g., tumor shrinkage or non-growth) should be especially strong for the expression change pattern to be used as a marker for efficacy.

[005] In order to survive and grow, solid tumors must acquire sufficient new vasculature to provide nutrients and oxygen by the process of angiogenesis. Vascular Endothelial Growth Factor (VEGF) and its receptor, Vascular Endothelial Growth Factor Receptor-2 (VEGFR2, aka KDR), which is expressed on activated endothelial cells found in association with growing, invading tumors, are absolutely required for this process. Signal transduction through the VEGF/VEGFR2 pathway is the primary stimulus for initiation and maintenance of tumor angiogenesis. Blocking the interaction of VEGF with VEGFR2 or inhibiting the tyrosine kinase activity of VEGFR2 blocks both angiogenesis and tumor growth *in vivo* in preclinical models. Complete suppression of tumor growth has been demonstrated using dominant negative VEGF receptors (Millauer, et al., *Cancer Res.* 56:1615-1620, 1996; Goldman, et al., *Proc. Natl. Acad. Sci. USA* 95:8795, 1998; Lin, et al., *J. Natl. Cancer Inst.* 87:213-219, 1995) and blocking antibodies (Kim, et al., *Nature* 362:841-844, 1993; Melnyk, et al., *Cancer Res.* 56:921-924, 1996; Borgstrom, et al., *Prostate* 35:1-10, 1998; Warren, et al., *J. Clin. Invest.* 95:1789-1797, 1995; Asano, et al., *Cancer Res.* 55:5296-5301, 1995; Yuan, et al., *Proc. Natl. Acad. Sci. USA* 93:14765-14770, 1996) as well as small molecule inhibitors of VEGFR2 kinase activity (Abstract, Boston Angiogenesis Conference, March 22-23, 1999; Xu, et al., *Int. J. Oncol.* 16:445-454, 1997) as single-agent therapies in such models. Furthermore, this is a unique approach that is compatible with existing anticancer therapies as well as many agents in preclinical development.

[006] Targeting VEGFR2 on vascular endothelial cells has the key advantage that these normal cells, unlike genetically unstable tumors, are not likely to become drug resistant. Furthermore, VEGFR2 is not normally expressed on quiescent endothelial cells but is up-regulated in response to angiogenic stimuli. This situation offers a potentially favorable therapeutic index as a result of the selective expression of the drug target in tumor-associated vascular endothelium. Moreover, the data also suggests that small molecule inhibitors of VEGFR2 kinase activity will be an important therapeutic mechanism in the treatment of cancer.

[007] Stanniocalcin-1 (SEQ ID NO: 1 and 2) is a secreted glycoprotein originally identified as a hormone involved in calcium and phosphate homeostasis in bony fishes (Chang, et al., *Mol. Cell. Endocrinol.* 112:241-247, 1995). A second stanniocalcin, stanniocalcin-2 (SEQ ID NO: 3 and 4), has also been identified which shows significant similarity to stanniocalcin-1 (Chang, et al., *Mol.*

Cell. Endocrinol. 141:95-99, 1998). Stanniocalcin is induced by VEGF (Liu, et al., Arterioscler. Thromb. Vasc. Biol., epub Oct. 2, 2003). Stanniocalcin is up-regulated in *in vitro* models of angiogenesis and its expression is intense in the vasculature regions of colon carcinomas, all suggesting a prominent role for stanniocalcin in tumor angiogenesis (Gerritsen, et al., Exp. Nephrol. 10:114-119, 2002).

[008] The present invention describes the link between stanniocalcin and VEGFR2. That is, it has been demonstrated that expression of the stanniocalcin gene in cancer cells is altered following exposure to a VEGFR2 inhibitor (Figure 1). Therefore, stanniocalcin may serve as a valuable biomaker for tumor progression and differentiation and as a biomarker to monitor the efficacy of treatment with a VEGFR2 inhibitor.

SUMMARY OF THE INVENTION

[009] The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of stanniocalcin as a biomarker for a VEGFR2 inhibitor.

[010] In addition, it is an objective of the invention to provide methods and reagents for the prediction, diagnosis, prognosis, and therapy of cancer.

[011] In one embodiment of the present invention, the biomarkers comprise one or more genes and/or gene products that demonstrate altered expression following exposure to a drug. In a further embodiment, the drug is a VEGFR2 inhibitor, and in another embodiment, the biomarker is stanniocalcin.

[012] Another embodiment of the present invention is a method for screening the effects of a drug on a tissue or cell sample comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels in the tissue or cell sample are analyzed before and after exposure to the drug, and a variation in the expression level of the gene and/or gene product is indicative of a drug effect or provides a patient diagnosis or predicts a patient's response to the treatment. In a further embodiment, the drug is a VEGFR2 inhibitor. In another embodiment, the gene or gene product is stanniocalcin.

[013] Another aspect of the present invention is a method for discovering novel drugs comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels of the cells are analyzed before and after exposure to the drug, and a variation in the expression level of the gene and/or gene

product is indicative of drug efficacy. In a further aspect, the gene or gene product is stanniocalcin.

[014] The invention further provides a method for identifying a compound useful for the treatment of cancer comprising administering to a subject with cancer a test compound, and measuring the activity of the polypeptide, wherein a change in the activity of the polypeptide is indicative of the test compound being useful for the treatment of cancer. In a further embodiment, the polypeptide is stanniocalcin, and in another embodiment, the compound is a VEGFR2 inhibitor.

[015] The invention, thus, provides methods which may be used to identify compounds which may act, for example, as regulators or modulators such as agonists and antagonists, partial agonists, inverse agonists, activators, co-activators, and inhibitors. Accordingly, the invention provides reagents and methods for regulating the expression of a polynucleotide or a polypeptide associated with cancer. Reagents that modulate the expression, stability, or amount of a polynucleotide or the activity of the polypeptide may be a protein, a peptide, a peptidomimetic, a nucleic acid, a nucleic acid analogue (e.g., peptide nucleic acid, locked nucleic acid), or a small molecule.

[016] The present invention also provides a method for providing a patient diagnosis comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels of normal and patient samples are analyzed, and a variation in the expression level of the gene and/or gene product in the patient sample is diagnostic of a disease. The patient samples include, but are not limited to, blood, amniotic fluid, plasma, semen, bone marrow, and tissue biopsy. In a further embodiment, the gene or gene product is stanniocalcin.

[017] The present invention still further provides a method of diagnosing cancer in a subject comprising measuring the activity of the polypeptide in a subject suspected of having cancer, wherein if there is a difference in the activity of the polypeptide, relative to the activity of the polypeptide in a subject not suspected of having cancer, then the subject is diagnosed as having cancer. In a further embodiment, the polypeptide is stanniocalcin.

[018] In another embodiment, the invention provides a method for detecting cancer in a patient sample in which an antibody to a protein is used to react with proteins in the patient sample. In a still further embodiment, the antibody is specific for stanniocalcin.

[019] Another aspect of the present invention is a method for distinguishing between normal and disease states comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels of normal and disease

tissues are analyzed, and a variation in the expression level of the gene and/or gene product is indicative of a disease state. In a further aspect, the gene or gene product is stanniocalcin.

[020] In another embodiment, the invention pertains to a method of determining the phenotype of cells comprising detecting the differential expression, relative to normal cells, of at least one gene, wherein the gene is differentially expressed as compared to normal cells. In a further embodiment, the gene encodes stanniocalcin.

[021] In yet another embodiment, the invention pertains to a method of determining the phenotype of cells, comprising detecting the differential expression, relative to normal cells, of at least one polypeptide, wherein the protein is differentially expressed as compared to normal cells. In a further embodiment, the polypeptide is stanniocalcin.

[022] In another embodiment, the invention pertains to a method for determining the phenotype of cells from a patient by providing a nucleic acid probe comprising a nucleotide sequence having at least about 10, at least about 15, at least about 25, or at least about 40 consecutive nucleotides, obtaining a sample of cells from a patient, optionally providing a second sample of cells substantially all of which are non-cancerous, contacting the nucleic acid probe under stringent conditions with mRNA of each of said first and second cell samples, and comparing (a) the amount of hybridization of the probe with mRNA of the first cell sample, with (b) the amount of hybridization of the probe with mRNA of the second cell sample, wherein a difference in the amount of hybridization with the mRNA of the first cell sample as compared to the amount of hybridization with the mRNA of the second cell sample is indicative of the phenotype of cells in the first cell sample. In a further embodiment, the nucleic acid probe comprises the nucleotide sequence encoding stanniocalcin.

[023] In another embodiment, the invention provides a test kit for identifying the presence of cancerous cells or tissues, comprising a probe/primer, for measuring a level of a nucleic acid in a sample of cells isolated from a patient. In certain embodiments, the kit may further include instructions for using the kit, solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a nucleic acid susceptible to hybridization, solutions for lysing cells, or solutions for the purification of nucleic acids. In a further embodiment, the probe/primer comprises the nucleotide sequence encoding stanniocalcin.

[024] In one embodiment, the invention provides a test kit for identifying the presence of cancer cells or tissues, comprising an antibody specific for a protein. In certain embodiments, the kit further includes instructions for using the kit. In certain embodiments, the kit may further include solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a polypeptide susceptible to the binding of an antibody, solutions for lysing cells, or solutions for the

purification of polypeptides. In a still further embodiment, the antibody is specific for stanniocalcin.

[025] In another embodiment, the invention provides a test kit for monitoring the efficacy of a compound or therapeutic in cancerous cells or tissues, comprising a probe/primer, for measuring a level of a nucleic acid in a sample of cells isolated from a patient. In certain embodiments, the kit may further include instructions for using the kit, solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a nucleic acid susceptible to hybridization, solutions for lysing cells, or solutions for the purification of nucleic acids. In a further embodiment, the probe/primer comprises the nucleotide sequence encoding stanniocalcin.

[026] In one embodiment, the invention provides a test kit for monitoring the efficacy of a compound or therapeutic in cancer cells or tissues, comprising an antibody specific for a protein. In certain embodiments, the kit further includes instructions for using the kit. In certain embodiments, the kit may further include solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a polypeptide susceptible to the binding of an antibody, solutions for lysing cells, or solutions for the purification of polypeptides. In a still further embodiment, the antibody is specific for stanniocalcin.

DESCRIPTION OF THE FIGURES

[027] *Figure 1.* The effect of a VEGFR2 inhibitor on stanniocalcin-1 and stanniocalcin-2 expression in MDA-MB-231 xenograft tumors.

[028] *Figure 2A.* Stanniocalcin expression in HMVEC cells treated with 100 nM VEGFR2 inhibitor +/- VEGF.

[029] *Figure 2B.* A time course of stanniocalcin expression in HMVEC cells treated with 100 nM VEGFR2 inhibitor +/- VEGF.

[030] *Figure 3A.* A time course of stanniocalcin expression in HUVEC cells treated with 100 nM VEGFR2 inhibitor +/- VEGF.

[031] *Figure 3B.* Stanniocalcin expression in HUVEC cells treated with 100 nM VEGFR2 inhibitor +/- VEGF.

DETAILED DESCRIPTION OF THE INVENTION

[032] It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[033] It must be noted that as used herein and in the appended claims, the singular forms “a,” “and,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a gene” is a reference to one or more genes and includes equivalents thereof known to those skilled in the art, and so forth.

[034] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.

[035] All publications and patents mentioned herein are hereby incorporated herein by reference for the purpose of describing and disclosing, for example, the constructs and methodologies that are described in the publications which might be used in connection with the presently described invention. The publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.

Definitions

[036] For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided below.

[037] An “address” on an array (e.g., a microarray) refers to a location at which an element, for example, an oligonucleotide, is attached to the solid surface of the array.

[038] The term “agonist,” as used herein, is meant to refer to an agent that mimics or up-regulates (e.g., potentiates or supplements) the bioactivity of a protein. An agonist may be a wild-type protein or derivative thereof having at least one bioactivity of the wild-type protein. An agonist may also be a compound that up-regulates expression of a gene or which increases at least one bioactivity of a protein. An agonist can also be a compound which increases the interaction of a polypeptide with another molecule, for example, a target peptide or nucleic acid.

[039] “Amplification,” as used herein, relates to the production of additional copies of a nucleic acid sequence. For example, amplification may be carried out using polymerase chain reaction (PCR) technologies which are well known in the art. (*see, e.g.*, Dieffenbach and Dveksler (1995) *PCR Primer, A Laboratory Manual*, Cold Spring Harbor Press, Plainview, N.Y.)

[040] “Antagonist,” as used herein, is meant to refer to an agent that down-regulates (e.g., suppresses or inhibits) at least one bioactivity of a protein. For example, a VEGFR2 inhibitor is an example of such an antagonist. An antagonist may be a compound which inhibits or decreases the interaction between a protein and another molecule, for example, a target peptide or enzyme substrate. An antagonist may also be a compound that down-regulates expression of a gene or which reduces the amount of expressed protein present.

[041] The term “antibody,” as used herein, is intended to include whole antibodies, for example, of any isotype (IgG, IgA, IgM, IgE, etc.), and includes fragments thereof which are also specifically reactive with a vertebrate (e.g., mammalian) protein. Antibodies may be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. Thus, the term includes segments of proteolytically-cleaved or recombinantly-prepared portions of an antibody molecule that are capable of selectively reacting with a certain protein. Non-limiting examples of such proteolytic and/or recombinant fragments include Fab, F(ab')₂, Fab', Fv, and single chain antibodies (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker. The scFv's may be covalently or non-covalently linked to form antibodies having two or more binding sites. The subject invention includes polyclonal, monoclonal, or other purified preparations of antibodies and recombinant antibodies.

[042] The terms “array” or “matrix” refer to an arrangement of addressable locations or “addresses” on a device. The locations can be arranged in two-dimensional arrays, three-dimensional arrays, or other matrix formats. The number of locations may range from several to at least hundreds of thousands. Most importantly, each location represents a totally independent reaction site. A “nucleic acid array” refers to an array containing nucleic acid probes, such as oligonucleotides or larger portions of genes. The nucleic acid on the array is preferably single-stranded. Arrays wherein the probes are oligonucleotides are referred to as “oligonucleotide arrays” or “oligonucleotide chips.” A “microarray,” also referred to herein as a “biochip” or “biological chip,” is an array of regions having a density of discrete regions of at least about 100/cm², and preferably at least about 1000/cm². The regions in a microarray have typical dimensions, for example, diameters, in the range of between about 10-250 μm, and are separated from other regions in the array by about the same distance.

[043] “Biological activity” or “bioactivity” or “activity” or “biological function,” which are used interchangeably, herein mean an effector or antigenic function that is directly or indirectly

performed by a polypeptide (whether in its native or denatured conformation), or by any subsequence thereof. Biological activities include binding to polypeptides, binding to other proteins or molecules, activity as a DNA binding protein, as a transcription regulator, ability to bind damaged DNA, etc. A bioactivity can be modulated by directly affecting the subject polypeptide. Alternatively, a bioactivity can be altered by modulating the level of the polypeptide, such as by modulating expression of the corresponding gene.

[044] The term “biological sample,” as used herein, refers to a sample obtained from an organism or from components (e.g., cells) of an organism. The sample may be of any biological tissue or fluid. The sample may be a sample which is derived from a patient. Such samples include, but are not limited to, sputum, blood, blood cells (e.g., white cells), tissue or biopsy samples (e.g., tumor biopsy), urine, peritoneal fluid, and pleural fluid, or cells therefrom. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes.

[045] The term “biomarker” or “marker” encompasses a broad range of intra- and extra-cellular events as well as whole-organism physiological changes. Biomarkers may be represent essentially any aspect of cell function, for example, but not limited to, levels or rate of production of signaling molecules, transcription factors, metabolites, gene transcripts as well as post-translational modifications of proteins. Biomarkers may include whole genome analysis of transcript levels or whole proteome analysis of protein levels and/or modifications.

[046] A biomarker may also refer to a gene or gene product which is up- or down-regulated in a compound-treated, diseased cell of a subject having the disease compared to an untreated diseased cell. That is, the gene or gene product is sufficiently specific to the treated cell that it may be used, optionally with other genes or gene products, to identify, predict, or detect efficacy of a small molecule. Thus, a biomarker is a gene or gene product that is characteristic of efficacy of a compound in a diseased cell or the response of that diseased cell to treatment by the compound.

[047] A nucleotide sequence is “complementary” to another nucleotide sequence if each of the bases of the two sequences match, that is, are capable of forming Watson-Crick base pairs. The term “complementary strand” is used herein interchangeably with the term “complement.” The complement of a nucleic acid strand may be the complement of a coding strand or the complement of a non-coding strand.

[048] “Detection agents of genes” refers to agents that can be used to specifically detect the gene or other biological molecules relating to it, for example, RNA transcribed from the gene or polypeptides encoded by the gene. Exemplary detection agents are nucleic acid probes, which hybridize to nucleic acids corresponding to the gene, and antibodies.

[049] The term “cancer” includes, but is not limited to, solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid, and their distant metastases. The term also includes lymphomas, sarcomas, and leukemias.

[050] Examples of breast cancer include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma *in situ*, and lobular carcinoma *in situ*.

[051] Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.

[052] Examples of brain cancers include, but are not limited to, brain stem and hypophthalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.

[053] Tumors of the male reproductive organs include, but are not limited to, prostate and testicular cancer. Tumors of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.

[054] Tumors of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.

[055] Tumors of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, and urethral cancers.

[056] Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma.

[057] Examples of liver cancers include, but are not limited to, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.

[058] Skin cancers include, but are not limited to, squamous cell carcinoma, Kaposi’s sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.

[059] Head-and-neck cancers include, but are not limited to, laryngeal / hypopharyngeal / nasopharyngeal / oropharyngeal cancer, and lip and oral cavity cancer.

[060] Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin’s lymphoma, cutaneous T-cell lymphoma, Hodgkin’s disease, and lymphoma of the central nervous system.

[061] Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.

[062] Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.

[063] "A diseased cell of cancer" refers to a cell present in subjects having cancer. That is, a cell which is a modified form of a normal cell and is not present in a subject not having cancer, or a cell which is present in significantly higher or lower numbers in subjects having cancer relative to subjects not having cancer.

[064] The term "equivalent" is understood to include nucleotide sequences encoding functionally equivalent polypeptides. Equivalent nucleotide sequences may include sequences that differ by one or more nucleotide substitutions, additions, or deletions, such as allelic variants.

[065] The term "expression profile," which is used interchangeably herein with "gene expression profile" and "fingerprint" of a cell refers to a set of values representing mRNA levels of one or more genes in a cell. An expression profile preferably comprises values representing expression levels of at least about 10 genes, preferably at least about 50, 100, 200 or more genes. Expression profiles may also comprise an mRNA level of a gene which is expressed at similar levels in multiple cells and conditions (e.g., a housekeeping gene such as GAPDH). For example, an expression profile of a diseased cell of cancer refers to a set of values representing mRNA levels of 10 or more genes in a diseased cell.

[066] The term "gene" refers to a nucleic acid sequence that comprises control and coding sequences necessary for the production of a polypeptide or precursor. The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence. The gene may be derived in whole or in part from any source known to the art, including a plant, a fungus, an animal, a bacterial genome or episome, eukaryotic, nuclear or plasmid DNA, cDNA, viral DNA, or chemically synthesized DNA. A gene may contain one or more modifications in either the coding or the untranslated regions which could affect the biological activity or the chemical structure of the expression product, the rate of expression, or the manner of expression control. Such modifications include, but are not limited to, mutations, insertions, deletions, and substitutions of one or more nucleotides. The gene may constitute an uninterrupted coding sequence or it may include one or more introns, bound by the appropriate splice junctions.

[067] "Hybridization" refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing. For example, two single-stranded nucleic acids "hybridize" when they form a double-stranded duplex. The region of double-strandedness may include the full-length of one or both of the single-stranded nucleic acids, or all of one single-stranded nucleic acid and a subsequence of the other single-stranded nucleic acid, or the region of double-strandedness may include a subsequence of each nucleic acid. Hybridization also includes the formation of duplexes which contain certain mismatches, provided that the two strands are still

forming a double-stranded helix. "Stringent hybridization conditions" refers to hybridization conditions resulting in essentially specific hybridization.

[068] The term "isolated," as used herein, with respect to nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs or RNAs, respectively, that are present in the natural source of the macromolecule. The term "isolated" as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Moreover, an "isolated nucleic acid" may include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state. The term "isolated" is also used herein to refer to polypeptides which are substantially free of other cellular proteins and is meant to encompass both purified and recombinant polypeptides.

[069] As used herein, the terms "label" and "detectable label" refer to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, ligands (e.g., biotin or haptens), and the like. The term "fluorescer" refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range. Particular examples of labels which may be used in the present invention include fluorescein, rhodamine, dansyl, umbelliferone, Texas red, luminol, NADPH, alpha - beta -galactosidase, and horseradish peroxidase.

[070] As used herein, the term "level of expression" refers to the measurable expression level of a given nucleic acid. The level of expression of a nucleic acid is determined by methods well known in the art. The term "differentially expressed" or "differential expression" refers to an increase or decrease in the measurable expression level of a given nucleic acid. Absolute quantification of the level of expression of a nucleic acid may be accomplished by including a known concentration(s) of one or more control nucleic acid species, generating a standard curve based on the amount of the control nucleic acid and extrapolating the expression level of the "unknown" nucleic acid species from the hybridization intensities of the unknown with respect to the standard curve.

[071] As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA) and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs and, as applicable to the embodiment being described, single-stranded (sense or antisense) and double-stranded polynucleotides. Chromosomes, cDNAs, mRNAs, rRNAs, and ESTs are representative examples of molecules that may be referred to as nucleic acids.

[072] The term “oligonucleotide” as used herein refers to a nucleic acid molecule comprising, for example, from about 10 to about 1000 nucleotides. Oligonucleotides for use in the present invention are preferably from about 15 to about 150 nucleotides, more preferably from about 150 to about 1000 in length. The oligonucleotide may be a naturally occurring oligonucleotide or a synthetic oligonucleotide. Oligonucleotides may be prepared by the phosphoramidite method (Beaucage and Carruthers, *Tetrahedron Lett.* 22:1859-62, 1981), or by the triester method (Matteucci, et al., *J. Am. Chem. Soc.* 103:3185, 1981), or by other chemical methods known in the art.

[073] The term “patient” or “subject” as used herein includes mammals (e.g., humans and animals such as dogs, cats, etc.).

[074] As used herein, a nucleic acid or other molecule attached to an array is referred to as a “probe” or “capture probe.” When an array contains several probes corresponding to one gene, these probes are referred to as a “gene-probe set.” A gene-probe set may consist of, for example, about 2 to about 20 probes, preferably from about 2 to about 10 probes, and most preferably about 5 probes.

[075] The “profile” of a cell’s biological state refers to the levels of various constituents of a cell that are known to change in response to drug treatments and other perturbations of the biological state of the cell. Constituents of a cell include, for example, levels of RNA, levels of protein abundances, or protein activity levels.

[076] The term “protein” is used interchangeably herein with the terms “peptide” and “polypeptide.”

[077] “Small molecule,” as used herein, refers to a composition with a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids, or other organic or inorganic molecules. Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures, often fungal, bacterial, or algal extracts, which can be screened with any of the assays of the invention to identify compounds that modulate a bioactivity.

[078] The term “specific hybridization” of a probe to a target site of a template nucleic acid refers to hybridization of the probe predominantly to the target, such that the hybridization signal can be clearly interpreted. As further described herein, such conditions resulting in specific hybridization vary depending on the length of the region of homology, the GC content of the region, and the melting temperature (“ T_m ”) of the hybrid. Thus, hybridization conditions may vary in salt content, acidity, and temperature of the hybridization solution and the washes.

[079] A “variant” of polypeptide refers to a polypeptide having an amino acid sequence in which one or more amino acid residues is altered. The variant may have “conservative” changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). A variant may also have “nonconservative” changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be identified using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

[080] The term “variant,” when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to that of a particular gene or the coding sequence thereof. This definition may also include, for example, “allelic,” “splice,” “species,” or “polymorphic” variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass “single nucleotide polymorphisms” (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

[081] An aspect of the invention is directed to the identification of agents capable of modulating the differentiation and proliferation of cells characterized by aberrant proliferation. More specifically, the invention relates to methods of screening candidate compounds or substances for their ability to regulate the differential expression of nucleic acid sequences. That is, if a nucleic acid sequence is overexpressed in cancer cells, then the candidate compounds are screened for their ability to decrease expression, and if a nucleic acid sequence is underexpressed in cancer cells, then a test compound is screened for its ability to increase expression. In addition, the invention relates to screening assays to identify test compounds or substances which modulate the activity of one or more polypeptides which are encoded by the differentially expressed sequences described herein. In this regard, the invention provides assays for determining compounds that modulate the expression of marker nucleic acids and/or alter the bioactivity of the encoded polypeptide.

Screening for modulation of differential expression

[082] Drug screening is performed by adding a test compound (e.g., VEGFR2 inhibitor) to a sample of cells, and monitoring the effect. A parallel sample which does not receive the test compound is also monitored as a control. The treated and untreated cells are then compared by any suitable phenotypic criteria, including but not limited to microscopic analysis, viability testing, ability to replicate, histological examination, the level of a particular RNA or polypeptide associated with the cells, the level of enzymatic activity expressed by the cells or cell lysates, and the ability of the cells to interact with other cells or compounds. Differences between treated and untreated cells indicates effects attributable to the test compound.

[083] Desirable effects of a test compound include an effect on any phenotype that was conferred by the cancer-associated marker nucleic acid sequence. Examples include a test compound that limits the overabundance of mRNA, limits production of the encoded protein, or limits the functional effect of the protein. The effect of the test compound would be apparent when comparing results between treated and untreated cells.

[084] The invention thus, also encompasses methods of screening for agents (e.g., VEGFR2 inhibitor) which inhibit or enhance the expression of the nucleic acid markers *in vitro*, comprising exposing a cell or tissue in which the marker nucleic acid mRNA (e.g., stanniocalcin) is detectable in cultured cells to an agent in order to determine whether the agent is capable of inhibiting or enhancing production of the mRNA; and determining the level of mRNA in the exposed cells or tissue, wherein a decrease in the level of the mRNA after exposure of the cell line to the agent is indicative of inhibition of the marker nucleic acid mRNA production and an increase in mRNA levels is indicative of enhancement of marker mRNA production.

[085] Alternatively, the screening method may include *in vitro* screening of a cell or tissue in which marker protein is detectable in cultured cells to an agent suspected of inhibiting or enhancing production of the marker protein; and determining the level of the marker protein in the cells or tissue, wherein a decrease in the level of marker protein after exposure of the cells or tissue to the agent is indicative of inhibition of marker protein production and an increase on the level of marker protein is indicative of enhancement of marker protein production.

[086] The invention also encompasses *in vivo* methods of screening for agents which inhibit or enhance expression of the marker nucleic acids, comprising exposing a subject having tumor cells in which marker mRNA or protein is detectable to an agent suspected of inhibiting or enhancing production of marker mRNA or protein; and determining the level of marker mRNA or protein in tumor cells of the exposed mammal. A decrease in the level of marker mRNA or protein after exposure of the subject to the agent is indicative of inhibition of marker nucleic acid expression and an increase in the level of marker mRNA or protein is indicative of enhancement of marker nucleic acid expression.

[087] Accordingly, the invention provides a method comprising incubating a cell expressing the marker nucleic acids with a test compound and measuring the mRNA or protein level. The invention further provides a method for quantitatively determining the level of expression of the marker nucleic acids in a cell population, and a method for determining whether an agent is capable of increasing or decreasing the level of expression of the marker nucleic acids in a cell population. The method for determining whether an agent is capable of increasing or decreasing the level of expression of the marker nucleic acids in a cell population comprises the steps of (a) preparing cell extracts from control and agent-treated cell populations, (b) isolating the marker polypeptides from the cell extracts, and (c) quantifying (e.g., in parallel) the amount of an immunocomplex formed between the marker polypeptide and an antibody specific to said polypeptide. The marker polypeptides of this invention may also be quantified by assaying for its bioactivity. Agents that induce an increase in the marker nucleic acid expression may be identified by their ability to increase the amount of immunocomplex formed in the treated cell as compared with the amount of the immunocomplex formed in the control cell. In a similar manner, agents that decrease expression of the marker nucleic acid may be identified by their ability to decrease the amount of the immunocomplex formed in the treated cell extract as compared to the control cell.

[088] The present invention provides isolated nucleic acid sequences which are differentially regulated in cancer, and a method for identifying such sequences. The present invention provides a method for identifying a nucleotide sequence which is differentially regulated in a subject with cancer, comprising: hybridizing a nucleic acid sample corresponding to RNA obtained from the subject to a nucleic acid sample comprising one or more nucleic acid molecules of known identity; and measuring the hybridization of the nucleic acid sample to the one or more nucleic acid molecules of known identity, wherein, for example, a difference in the hybridization of the nucleic acid sample to the one or more nucleic acid molecules of known identity relative to a nucleic acid sample obtained from a subject without cancer is indicative of the differential expression of the nucleotide sequence in a subject with cancer.

[089] Generally, the present invention provides a method for identifying nucleic acid sequences which are differentially regulated in a subject with cancer comprising isolating messenger RNA from a subject, generating cRNA from the mRNA sample, hybridizing the cRNA to a microarray comprising a plurality of nucleic acid molecules stably associated with discrete locations on the array, and identifying patterns of hybridization of the cRNA to the array. According to the present invention, a nucleic acid molecule which hybridizes to a given location on the array is said to be differentially regulated if the hybridization signal is, for example, higher or lower than the hybridization signal at the same location on an identical array hybridized with a nucleic acid sample obtained from a subject that does not have cancer.

Microarrays for Determining the Level of Expression of Genes

[090] Determining gene expression levels may be accomplished utilizing microarrays.

Generally, the following steps may be involved: (a) obtaining an mRNA sample from a subject and preparing labeled nucleic acids therefrom (the “target nucleic acids” or “targets”); (b) contacting the target nucleic acids with an array under conditions sufficient for the target nucleic acids to bind to the corresponding probes on the array, for example, by hybridization or specific binding; (c) optional removal of unbound targets from the array; (d) detecting the bound targets, and (e) analyzing the results, for example, using computer based analysis methods. As used herein, “nucleic acid probes” or “probes” are nucleic acids attached to the array, whereas “target nucleic acids” are nucleic acids that are hybridized to the array.

[091] Nucleic acid specimens may be obtained from a subject to be tested using either “invasive” or “non-invasive” sampling means. A sampling means is said to be “invasive” if it involves the collection of nucleic acids from within the skin or organs of an animal (including murine, human, ovine, equine, bovine, porcine, canine, or feline animal). Examples of invasive methods include, for example, blood collection, semen collection, needle biopsy, pleural aspiration, umbilical cord biopsy. Examples of such methods are discussed by Kim, et al., (J. Virol. 66:3879-3882, 1992); Biswas, et al., (Ann. NY Acad. Sci. 590:582-583, 1990); and Biswas, et al., (J. Clin. Microbiol. 29:2228-2233, 1991).

[092] In contrast, a “non-invasive” sampling means is one in which the nucleic acid molecules are recovered from an internal or external surface of the animal. Examples of such “non-invasive” sampling means include, for example, “swabbing,” collection of tears, saliva, urine, fecal material, sweat or perspiration, hair.

[093] In one embodiment of the present invention, one or more cells from the subject to be tested are obtained and RNA is isolated from the cells. In a preferred embodiment, a sample of peripheral blood leukocytes (PBLs) cells is obtained from the subject. It is also possible to obtain a cell sample from a subject, and then to enrich the sample for a desired cell type. For example, cells may be isolated from other cells using a variety of techniques, such as isolation with an antibody binding to an epitope on the cell surface of the desired cell type. Where the desired cells are in a solid tissue, particular cells may be dissected, for example, by microdissection or by laser capture microdissection (LCM) (*see, e.g.*, Bonner, et al., Science 278:1481, 1997; Emmert-Buck, et al., Science 274:998, 1996; Fend, et al., Am. J. Path. 154:61, 1999; and Murakami, et al., Kidney Int. 58:1346, 2000).

[094] RNA may be extracted from tissue or cell samples by a variety of methods, for example, guanidium thiocyanate lysis followed by CsCl centrifugation (Chirgwin, et al., Biochemistry 18:5294-5299, 1979). RNA from single cells may be obtained as described in methods for

preparing cDNA libraries from single cells (*see, e.g.*, Dulac, *Curr. Top. Dev. Biol.* 36:245, 1998; Jena, et al., *J. Immunol. Methods* 190:199, 1996).

[095] The RNA sample can be further enriched for a particular species. In one embodiment, for example, poly(A)⁺ RNA may be isolated from an RNA sample. In another embodiment, the RNA population may be enriched for sequences of interest by primer-specific cDNA synthesis, or multiple rounds of linear amplification based on cDNA synthesis and template-directed *in vitro* transcription (*see, e.g.*, Wang, et al., *Proc. Natl. Acad. Sci. USA* 86:9717, 1989; Dulac, et al., *supra*; Jena, et al., *supra*). In addition, the population of RNA, enriched or not in particular species or sequences, may be further amplified by a variety of amplification methods including, for example, PCR; ligase chain reaction (LCR) (*see, e.g.*, Wu and Wallace, *Genomics* 4:560, 1989; Landegren, et al., *Science* 241:1077, 1988); self-sustained sequence replication (SSR) (*see, e.g.*, Guatelli, et al., *Proc. Natl. Acad. Sci. USA* 87:1874, 1990); nucleic acid based sequence amplification (NASBA) and transcription amplification (*see, e.g.*, Kwok, et al., *Proc. Natl. Acad. Sci. USA* 86:1173, 1989). Methods for PCR technology are well known in the art (*see, e.g.*, *PCR Technology: Principles and Applications for DNA Amplification* (ed. H. A. Erlich, Freeman Press, N.Y., N.Y., 1992); *PCR Protocols: A Guide to Methods and Applications* (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila, et al., *Nucleic Acids Res.* 19:4967, 1991; Eckert, et al., *PCR Methods and Applications* 1:17, 1991; *PCR* (eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202). Methods of amplification are described, for example, by Ohyama, et al., (*BioTechniques* 29:530, 2000); Luo, et al., (*Nat. Med.* 5:117, 1999); Hegde, et al., (*BioTechniques* 29:548, 2000); Kacharina, et al., (*Meth. Enzymol.* 303:3, 1999); Livesey, et al., (*Curr. Biol.* 10:301, 2000); Spirin, et al., (*Invest. Ophthalmol. Vis. Sci.* 40:3108, 1999); and Sakai, et al., (*Anal. Biochem.* 287:32, 2000). RNA amplification and cDNA synthesis may also be conducted in cells *in situ* (*see, e.g.*, Eberwine, et al. *Proc. Natl. Acad. Sci. USA* 89:3010, 1992).

[096] The nucleic acid molecules may be labeled to permit detection of hybridization of the nucleic acid molecules to a microarray. That is, the probe may comprise a member of a signal producing system and thus, is detectable, either directly or through combined action with one or more additional members of a signal producing system. For example, the nucleic acids may be labeled with a fluorescently labeled dNTP (*see, e.g.*, Kricka, 1992, *Nonisotopic DNA Probe Techniques*, Academic Press San Diego, Calif.), biotinylated dNTPs or rNTP followed by addition of labeled streptavidin, chemiluminescent labels, or isotopes. Another example of labels include "molecular beacons" as described in Tyagi and Kramer (*Nature Biotech.* 14:303, 1996). Hybridization may be also be determined, for example, by plasmon resonance (*see, e.g.*, Thiel, et al. *Anal. Chem.* 69:4948, 1997).

[097] In one embodiment, a plurality (e.g., 2, 3, 4, 5, or more) of sets of target nucleic acids are labeled and used in one hybridization reaction ("multiplex" analysis). For example, one set of nucleic acids may correspond to RNA from one cell and another set of nucleic acids may correspond to RNA from another cell. The plurality of sets of nucleic acids may be labeled with different labels, for example, different fluorescent labels (e.g., fluorescein and rhodamine) which have distinct emission spectra so that they can be distinguished. The sets may then be mixed and hybridized simultaneously to one microarray (*see, e.g.*, Shena, et al., *Science* 270:467-470, 1995).

[098] Microarrays for use according to the invention include one or more probes of genes characteristic of small molecule efficacy. In a preferred embodiment, the microarray comprises probes corresponding to one or more of genes selected from the group consisting of genes which are up-regulated in cancer and genes which are down-regulated in cancer. The microarray may comprise probes corresponding to at least 10, preferably at least 20, at least 50, at least 100 or at least 1000 genes characteristic of small molecule efficacy.

[099] There may be one or more than one probe corresponding to each gene on a microarray. For example, a microarray may contain from 2 to 20 probes corresponding to one gene and preferably about 5 to 10. The probes may correspond to the full-length RNA sequence or complement thereof of genes characteristic of small molecule efficacy, or the probe may correspond to a portion thereof, which portion is of sufficient length to permit specific hybridization. Such probes may comprise from about 50 nucleotides to about 100, 200, 500, or 1000 nucleotides or more than 1000 nucleotides. As further described herein, microarrays may contain oligonucleotide probes, consisting of about 10 to 50 nucleotides, preferably about 15 to 30 nucleotides and more preferably about 20-25 nucleotides. The probes are preferably single-stranded and will have sufficient complementarity to its target to provide for the desired level of sequence specific hybridization.

[100] Typically, the arrays used in the present invention will have a site density of greater than 100 different probes per cm^2 . Preferably, the arrays will have a site density of greater than $500/\text{cm}^2$, more preferably greater than about $1000/\text{cm}^2$, and most preferably, greater than about $10,000/\text{cm}^2$. For example, the arrays will have more than 100 different probes on a single substrate, more preferably greater than about 1000 different probes, still more preferably, greater than about 10,000 different probes and most preferably, greater than 100,000 different probes on a single substrate.

[101] A number of different microarray configurations and methods for their production are known to those of skill in the art and are disclosed in U.S. Patent Nos: 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,445,934; 5,556,752; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,472,672; 5,527,681; 5,529,756; 5,545,531;

5,554,501; 5,561,071; 5,571,639; 5,593,839; 5,624,711; 5,700,637; 5,744,305; 5,770,456; 5,770,722; 5,837,832; 5,856,101; 5,874,219; 5,885,837; 5,919,523; 6,022,963; 6,077,674; and 6,156,501; Shena, et al., *Tibtech* 16:301, 1998; Duggan, et al., *Nat. Genet.* 21:10, 1999; Bowtell, et al., *Nat. Genet.* 21:25, 1999; Lipshutz, et al., *Nature Genet.* 21:20-24, 1999; Blanchard, et al., *Biosensors and Bioelectronics*, 11:687-90, 1996; Maskos, et al., *Nucleic Acids Res.* 21:4663-69, 1993; Hughes, et al., *Nat. Biotechnol.* 19:342, 2001; the disclosures of which are herein incorporated by reference. Patents describing methods of using arrays in various applications include: U.S. Pat. Nos. 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,848,659; and 5,874,219; the disclosures of which are herein incorporated by reference.

[102] Arrays preferably include control and reference nucleic acids. Control nucleic acids include, for example, prokaryotic genes such as bioB, bioC and bioD, cre from P1 bacteriophage or polyA controls, such as dap, lys, phe, thr, and trp. Reference nucleic acids allow the normalization of results from one experiment to another and the comparison of multiple experiments on a quantitative level. Exemplary reference nucleic acids include housekeeping genes of known expression levels, for example, GAPDH, hexokinase, and actin.

[103] In one embodiment, an array of oligonucleotides may be synthesized on a solid support. Exemplary solid supports include glass, plastics, polymers, metals, metalloids, ceramics, organics, etc. Using chip masking technologies and photoprotective chemistry, it is possible to generate ordered arrays of nucleic acid probes. These arrays, which are known, for example, as "DNA chips" or very large scale immobilized polymer arrays ("VLSIPSTM" arrays), may include millions of defined probe regions on a substrate having an area of about 1 cm² to several cm², thereby incorporating from a few to millions of probes (*see, e.g.*, U.S. Patent No. 5,631,734).

[104] To compare expression levels, labeled nucleic acids may be contacted with the array under conditions sufficient for binding between the target nucleic acid and the probe on the array. In a preferred embodiment, the hybridization conditions may be selected to provide for the desired level of hybridization specificity; that is, conditions sufficient for hybridization to occur between the labeled nucleic acids and probes on the microarray.

[105] Hybridization may be carried out in conditions permitting essentially specific hybridization. The length and GC content of the nucleic acid will determine the thermal melting point and thus, the hybridization conditions necessary for obtaining specific hybridization of the probe to the target nucleic acid. These factors are well known to a person of skill in the art, and may also be tested in assays. An extensive guide to nucleic acid hybridization may be found in Tijssen, et al. (*Laboratory Techniques in Biochemistry and Molecular Biology*, Vol. 24: Hybridization With Nucleic Acid Probes, P. Tijssen, ed. Elsevier, N.Y., (1993)).

[106] The methods described above result in the production of hybridization patterns of labeled target nucleic acids on the array surface. The resultant hybridization patterns of labeled nucleic acids may be visualized or detected in a variety of ways, with the particular manner of detection selected based on the particular label of the target nucleic acid. Representative detection means include scintillation counting, autoradiography, fluorescence measurement, colorimetric measurement, light emission measurement, light scattering, and the like.

[107] One such method of detection utilizes an array scanner that is commercially available (Affymetrix, Santa Clara, CA), for example, the 417TM Arrayer, the 418TM Array Scanner, or the Agilent GeneArrayTM Scanner. This scanner is controlled from a system computer with an interface and easy-to-use software tools. The output may be directly imported into or directly read by a variety of software applications. Preferred scanning devices are described in, for example, U.S. Patent Nos. 5,143,854 and 5,424,186.

[108] For fluorescent labeled probes, the fluorescence emissions at each site of a transcript array may be, preferably, detected by scanning confocal laser microscopy. Alternatively, a laser may be used that allows simultaneous specimen illumination at wavelengths specific to the two fluorophores and emissions from the two fluorophores may be analyzed simultaneously (*see, e.g.*, Shalon, et al., *Genome Res.* 6:639-645, 1996). In a preferred embodiment, the arrays may be scanned with a laser fluorescent scanner with a computer controlled X-Y stage and a microscope objective. Fluorescence laser scanning devices are described in Shalon, et al., *supra*.

[109] Various algorithms are available for analyzing gene expression data, for example, the type of comparisons to perform. In certain embodiments, it is desirable to group genes that are co-regulated. This allows for the comparison of large numbers of profiles. A preferred embodiment for identifying such groups of genes involves clustering algorithms (for reviews of clustering algorithms, *see, e.g.*, Fukunaga, 1990, *Statistical Pattern Recognition*, 2nd Ed., Academic Press, San Diego; Everitt, 1974, *Cluster Analysis*, London: Heinemann Educ. Books; Hartigan, 1975, *Clustering Algorithms*, New York: Wiley; Sneath and Sokal, 1973, *Numerical Taxonomy*, Freeman; Anderberg, 1973, *Cluster Analysis for Applications*, Academic Press: New York).

Biomarker Discovery

[110] Expression patterns may be used to derive a panel of biomarkers that can be used to predict the efficacy of drug treatment in the patients. The biomarkers may consist of gene expression levels from microarray experiments on RNA isolated from biological samples, RNA isolated from frozen samples of tumor biopsies, or mass spectrometry-derived protein masses in the serum.

[111] Although the precise mechanism for data analysis will depend upon the exact nature of the data, a typical procedure for developing a panel of biomarkers is as follows. The data (gene

expression levels or mass spectra) are collected for each patient prior to treatment. As the study progresses, the patients are classified according to their response to the drug treatment; either as efficacious or non-efficacious. Multiple levels of efficacy can be accommodated in a data model, but a binary comparison is considered optimal, particularly if the patient population is less than several hundred. Assuming adequate numbers of patients in each class, the protein and/or gene expression data may be analyzed by a number of techniques known in the art. Many of the techniques are derived from traditional statistics as well from the field of machine learning. These techniques serve two purposes:

1. Reduce the dimensionality of data - In the case of mass spectra or gene expression microarrays, data is reduced from many thousands of individual data points to about three to ten. The reduction is based upon the predictive power of the data points when taken as a set.

2. Training - These three to ten data points are then used to train multiple machine learning algorithms which then “learn” to recognize, in this case, patterns of protein masses or gene expression which distinguish efficacious drug treatment from non-efficacious. All patient samples can be used to train the algorithms.

[112] The resulting, trained, algorithms are then tested in order to measure their predictive power. Typically, when less than many hundreds of training examples are available, some form of cross-validation is performed. To illustrate, consider a ten-fold cross validation. In this case, patient samples are randomly assigned to one of ten bins. In the first round of validation the samples in nine of the bins are used for training and the remaining samples in the tenth bin are used to test the algorithm. This is repeated an additional nine times, each time leaving out the samples in a different bin for testing. The results (correct predictions and errors) from all ten rounds are combined and the predictive power is then assessed. Different algorithms, as well as different panels, may be compared in this way for this study. The “best” algorithm/panel combination will then be selected. This “smart” algorithm may then be used in future studies to select the patients that are most likely to respond to treatment.

[113] Many algorithms benefit from additional information taken for the patients. For example, gender or age could be used to improve predictive power. Also, data transformations such as normalization and smoothing may be used to reduce noise. Because of this, a large number of algorithms may be trained using many different parameters in order to optimize the outcome. If predictive patterns exist in the data, it is likely that an optimal, or near-optimal, “smart” algorithm can be developed. If more patient samples become available, the algorithm can be retrained to take advantage of the new data.

[114] As an example using mass spectrometry, plasma (1 μ l) may be applied to a hydrophobic SELDI-target, washed extensively in water, and analyzed by the SELDI-ToF mass spectrometer.

This may be repeated on 100 or more patient samples. The protein profiles resulting from the intensities of some 16,000 m/z values in each sample would be statistically analyzed in order to identify sets of specific m/z values that are predictive of drug efficacy. Identical experiments using other SELDI-targets, such as ion-exchange or IMAC surfaces, could also be conducted. These will capture different subsets of the proteins present in plasma. Furthermore, the plasma may be denatured and prefractionated prior to application onto the SELDI target.

Diagnostic & Prognostic Assays

[115] The present invention provides methods for determining whether a subject is at risk for developing a disease or condition characterized by unwanted cell proliferation by detecting biomarkers (e.g., stanniocalcin), that is, nucleic acids and/or polypeptide markers for cancer.

[116] In clinical applications, human tissue samples may be screened for the presence and/or absence of biomarkers identified herein. Such samples could consist of needle biopsy cores, surgical resection samples, lymph node tissue, or serum. For example, these methods include obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich tumor cells to about 80% of the total cell population. In certain embodiments, nucleic acids extracted from these samples may be amplified using techniques well known in the art. The levels of selected markers detected would be compared with statistically valid groups of metastatic, non-metastatic malignant, benign, or normal tissue samples.

[117] In one embodiment, the diagnostic method comprises determining whether a subject has an abnormal mRNA and/or protein level of the biomarkers (e.g., stanniocalcin), such as by Northern blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), *in situ* hybridization, immunoprecipitation, Western blot hybridization, or immunohistochemistry. According to the method, cells may be obtained from a subject and the levels of the biomarkers, protein, or mRNA level, are determined and compared to the level of these markers in a healthy subject. An abnormal level of the biomarker polypeptide or mRNA levels is likely to be indicative of cancer.

[118] Accordingly, in one aspect, the invention provides probes and primers that are specific to the unique nucleic acid markers disclosed herein. Accordingly, the nucleic acid probes comprise a nucleotide sequence at least 10 nucleotides in length, preferably at least 15 nucleotides, more preferably, 25 nucleotides, and most preferably at least 40 nucleotides, and up to all or nearly all of the coding sequence which is complementary to a portion of the coding sequence of a marker nucleic acid sequence.

[119] In one embodiment, the method comprises using a nucleic acid probe to determine the presence of cancerous cells in a tissue from a patient. For example, the method comprises:

1. providing a nucleic acid probe comprising a nucleotide sequence, for example, at least 10 nucleotides in length, at least 15 nucleotides, at least 25 nucleotides, or at least 40 nucleotides, and up to all or nearly all of the coding sequence which is complementary to a portion of the coding sequence of a nucleic acid sequence and is differentially expressed in tumors cells;
2. obtaining a tissue sample from a patient potentially comprising cancerous cells;
3. providing a second tissue sample containing cells substantially all of which are non-cancerous;
4. contacting the nucleic acid probe under stringent conditions with RNA of each of said first and second tissue samples (e.g., in a Northern blot or *in situ* hybridization assay); and
5. comparing (a) the amount of hybridization of the probe with RNA of the first tissue sample, with (b) the amount of hybridization of the probe with RNA of the second tissue sample; wherein a statistically significant difference in the amount of hybridization with the RNA of the first tissue sample as compared to the amount of hybridization with the RNA of the second tissue sample is indicative of the presence of cancerous cells in the first tissue sample.

[120] In one aspect, the method comprises *in situ* hybridization with a probe derived from a given marker nucleic acid sequence (e.g., stanniocalcin). The method comprises contacting the labeled hybridization probe with a sample of a given type of tissue potentially containing cancerous or pre-cancerous cells as well as normal cells, and determining whether the probe labels some cells of the given tissue type to a degree significantly different than the degree to which it labels other cells of the same tissue type.

[121] Also within the invention is a method of determining the phenotype of a test cell from a given human tissue, for example, whether the cell is (a) normal, or (b) cancerous or precancerous, by contacting the mRNA of a test cell with a nucleic acid probe, for example, at least 12 nucleotides in length, at least 15 nucleotides, at least 25 nucleotides, or at least 40 nucleotides, and up to all or nearly all of a sequence which is complementary to a portion of the coding sequence of a nucleic acid sequence, and which is differentially expressed in tumor cells as compared to normal cells of the given tissue type; and determining the approximate amount of hybridization of the probe to the mRNA, an amount of hybridization either more or less than that seen with the mRNA of a normal cell of that tissue type being indicative that the test cell is cancerous or precancerous.

[122] Alternatively, the above diagnostic assays may be carried out using antibodies to detect the protein product encoded by the marker nucleic acid sequence (e.g., stanniocalcin). Accordingly, in one embodiment, the assay would include contacting the proteins of the test cell with an antibody specific for the gene product of a nucleic acid, the marker nucleic acid being one which is expressed at a given control level in normal cells of the same tissue type as the test cell, and determining the approximate amount of immunocomplex formation by the antibody and the proteins of the test cell, wherein a statistically significant difference in the amount of the immunocomplex formed with the proteins of a test cell as compared to a normal cell of the same tissue type is an indication that the test cell is cancerous or pre-cancerous. Preferably, the antibody is specific for stanniocalcin.

[123] The method for producing polyclonal and/or monoclonal antibodies which specifically bind to polypeptides useful in the present invention is known to those of skill in the art and may be found in, for example, Dymecki, et al., (J. Biol. Chem. 267:4815, 1992); Boersma & Van Leeuwen, (J. Neurosci. Methods 51:317, 1994); Green, et al., (Cell 28:477, 1982); and Arnheiter, et al., (Nature 294:278, 1981).

[124] Another such method includes the steps of: providing an antibody specific for the gene product of a marker nucleic acid sequence, the gene product being present in cancerous tissue of a given tissue type at a level more or less than the level of the gene product in non-cancerous tissue of the same tissue type; obtaining from a patient a first sample of tissue of the given tissue type, which sample potentially includes cancerous cells; providing a second sample of tissue of the same tissue type (which may be from the same patient or from a normal control, for example, another individual or cultured cells), this second sample containing normal cells and essentially no cancerous cells; contacting the antibody with protein (which may be partially purified, in lysed but unfractionated cells, or *in situ*) of the first and second samples under conditions permitting immunocomplex formation between the antibody and the marker nucleic acid sequence product present in the samples; and comparing (a) the amount of immunocomplex formation in the first sample, with (b) the amount of immunocomplex formation in the second sample, wherein a statistically significant difference in the amount of immunocomplex formation in the first sample less as compared to the amount of immunocomplex formation in the second sample is indicative of the presence of cancerous cells in the first sample of tissue.

[125] The subject invention further provides a method of determining whether a cell sample obtained from a subject possesses an abnormal amount of marker polypeptide which comprises (a) obtaining a cell sample from the subject, (b) quantitatively determining the amount of the marker polypeptide in the sample so obtained, and (c) comparing the amount of the marker polypeptide so determined with a known standard, so as to thereby determine whether the cell sample obtained

from the subject possesses an abnormal amount of the marker polypeptide. Such marker polypeptides may be detected by immunohistochemical assays, dot-blot assays, ELISA, and the like.

[126] Immunoassays are commonly used to quantitate the levels of proteins in cell samples, and many other immunoassay techniques are known in the art. The invention is not limited to a particular assay procedure, and therefore, is intended to include both homogeneous and heterogeneous procedures. Exemplary immunoassays which may be conducted according to the invention include fluorescence polarization immunoassay (FPIA), fluorescence immunoassay (FIA), enzyme immunoassay (EIA), nephelometric inhibition immunoassay (NIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA). An indicator moiety, or label group, may be attached to the subject antibodies and is selected so as to meet the needs of various uses of the method which are often dictated by the availability of assay equipment and compatible immunoassay procedures. General techniques to be used in performing the various immunoassays noted above are known to those of ordinary skill in the art.

[127] In another embodiment, the level of the encoded product, or alternatively the level of the polypeptide, in a biological fluid (e.g., blood or urine) of a patient may be determined as a way of monitoring the level of expression of the marker nucleic acid sequence in cells of that patient. Such a method would include the steps of obtaining a sample of a biological fluid from the patient, contacting the sample (or proteins from the sample) with an antibody specific for an encoded marker polypeptide, and determining the amount of immune complex formation by the antibody, with the amount of immune complex formation being indicative of the level of the marker encoded product in the sample. This determination is particularly instructive when compared to the amount of immune complex formation by the same antibody in a control sample taken from a normal individual or in one or more samples previously or subsequently obtained from the same person.

[128] In another embodiment, the method may be used to determine the amount of marker polypeptide present in a cell, which in turn may be correlated with progression of a hyperproliferative disorder. The level of the marker polypeptide may be used predictively to evaluate whether a sample of cells contains cells which are, or are predisposed towards becoming, transformed cells. Moreover, the subject method may be used to assess the phenotype of cells which are known to be transformed, the phenotyping results being useful in planning a particular therapeutic regimen. For example, very high levels of the marker polypeptide in sample cells is a powerful diagnostic and prognostic marker for a cancer. The observation of marker polypeptide levels may be utilized in decisions regarding, for example, the use of more aggressive therapies.

[129] As set out above, one aspect of the present invention relates to diagnostic assays for determining, in the context of cells isolated from a patient, if the level of a marker polypeptide is

significantly reduced in the sample cells. The term “significantly reduced” refers to a cell phenotype wherein the cell possesses a reduced cellular amount of the marker polypeptide relative to a normal cell of similar tissue origin. For example, a cell may have less than about 50%, 25%, 10%, or 5% of the marker polypeptide compared to that of a normal control cell. In particular, the assay evaluates the level of marker polypeptide in the test cells and compares the measured level with marker polypeptide detected in at least one control cell, for example, a normal cell and/or a transformed cell of known phenotype.

[130] Of particular importance to the subject invention is the ability to quantitate the level of marker polypeptide as determined by the number of cells associated with a normal or abnormal marker polypeptide level. The number of cells with a particular marker polypeptide phenotype may then be correlated with patient prognosis. In one embodiment of the invention, the marker polypeptide phenotype of a lesion is determined as a percentage of cells in a biopsy which are found to have abnormally high/low levels of the marker polypeptide. Such expression may be detected by immunohistochemical assays, dot-blot assays, ELISA, and the like.

[131] Where tissue samples are employed, immunohistochemical staining may be used to determine the number of cells having the marker polypeptide phenotype. For such staining, a multiblock of tissue may be taken from the biopsy or other tissue sample and subjected to proteolytic hydrolysis, employing such agents as protease K or pepsin. In certain embodiments, it may be desirable to isolate a nuclear fraction from the sample cells and detect the level of the marker polypeptide in the nuclear fraction.

[132] The tissue samples are fixed by treatment with a reagent such as formalin, glutaraldehyde, methanol, or the like. The samples are then incubated with an antibody, preferably a monoclonal antibody, with binding specificity for the marker polypeptides. This antibody may be conjugated to a label for subsequent detection of binding. Samples are incubated for a time sufficient for formation of the immunocomplexes. Binding of the antibody is then detected by virtue of a label conjugated to this antibody. Where the antibody is unlabeled, a second labeled antibody may be employed, for example, which is specific for the isotype of the anti-marker polypeptide antibody. Examples of labels which may be employed include radionuclides, fluorescers, chemiluminescers, enzymes, and the like.

[133] Where enzymes are employed, the substrate for the enzyme may be added to the samples to provide a colored or fluorescent product. Examples of suitable enzymes for use in conjugates include horseradish peroxidase, alkaline phosphatase, malate dehydrogenase, and the like. Where not commercially available, such antibody-enzyme conjugates are readily produced by techniques known to those skilled in the art.

[134] In one embodiment, the assay is performed as a dot blot assay. The dot blot assay finds particular application where tissue samples are employed as it allows determination of the average amount of the marker polypeptide associated with a single cell by correlating the amount of marker polypeptide in a cell-free extract produced from a predetermined number of cells.

[135] It is well established in the cancer literature that tumor cells of the same type (e.g., breast and/or colon tumor cells) may not show uniformly increased expression of individual oncogenes or uniformly decreased expression of individual tumor suppressor genes. There may also be varying levels of expression of a given marker gene even between cells of a given type of cancer, further emphasizing the need for reliance on a battery of tests rather than a single test. Accordingly, in one aspect, the invention provides for a battery of tests utilizing a number of probes of the invention, in order to improve the reliability and/or accuracy of the diagnostic test.

[136] In one embodiment, the present invention also provides a method wherein nucleic acid probes are immobilized on a DNA chip in an organized array. Oligonucleotides may be bound to a solid support by a variety of processes, including lithography. For example, a chip may hold up to 250,000 oligonucleotides. These nucleic acid probes comprise a nucleotide sequence at least about 12 nucleotides in length, preferably at least about 15 nucleotides, more preferably at least about 25 nucleotides, and most preferably at least about 40 nucleotides, and up to all or nearly all of a sequence which is complementary to a portion of the coding sequence of a marker nucleic acid sequence and is differentially expressed in tumor cells. The present invention provides significant advantages over the available tests for various cancers, because it increases the reliability of the test by providing an array of nucleic acid markers on a single chip.

[137] The method includes obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich tumor cells to about 80% of the total cell population. The DNA or RNA is then extracted, amplified, and analyzed with a DNA chip to determine the presence or absence of the marker nucleic acid sequences.

[138] In one embodiment, the nucleic acid probes are spotted onto a substrate in a two-dimensional matrix or array. Samples of nucleic acids may be labeled and then hybridized to the probes. Double-stranded nucleic acids, comprising the labeled sample nucleic acids bound to probe nucleic acids, may be detected once the unbound portion of the sample is washed away.

[139] The probe nucleic acids may be spotted on substrates including glass, nitrocellulose, etc. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. The sample nucleic acids can be labeled using radioactive labels, fluorophores, chromophores, etc.

[140] Techniques for constructing arrays and methods of using these arrays are described, for example, in EP No. 0 799 897; PCT No. WO 97/292 12; PCT No. WO 97127317; EP No. 0 785 280; PCT No. WO 97/02357; U.S. Pat. No. 5,593,839; U.S. Pat. No. 5,578,832; EP No. 0 728 520; U.S. Pat. No. 5,599,695; EP No. 0 721 016; U.S. Pat. No. 5,556,752; PCT No. WO 95/22058; and U.S. Pat. No. 5,631,734.

[141] Further, arrays may be used to examine differential expression of genes and may be used to determine gene function. For example, arrays of nucleic acid sequences may be used to determine if any of the nucleic acid sequences are differentially expressed between normal cells and cancer cells. Increased expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, may indicate a cancer-specific protein.

[142] In one embodiment, nucleic acid molecules may be used to generate microarrays on a solid surface (e.g., a membrane) such that the arrayed nucleic acid molecules may be used to determine if any of the nucleic acids are differentially expressed between normal cells or tissue and cancerous cells or tissue. In one embodiment, the nucleic acid molecules of the invention may be cDNA or may be used to generate cDNA molecules to be subsequently amplified by PCR and spotted on nylon membranes. The membranes may then be reacted with radiolabeled target nucleic acid molecules obtained from equivalent samples of cancerous and normal tissue or cells. Methods of cDNA generation and microarray preparation are known to those of skill in the art and may be found, for example, in Bertucci, et al., (*Hum. Mol. Genet.* 8:2129, 1999); Nguyen, et al., (*Genomics* 29:207, 1995); Zhao, et al., (*Gene* 156:207); Gress, et al., (*Mammalian Genome* 3:609, 1992); Zhumabayeva, et al., (*Biotechniques* 30:158, 2001); and Lennon, et al., (*Trends Genet.* 7:314, 1991).

[143] In yet another embodiment, the invention contemplates using a panel of antibodies which are generated against the marker polypeptides of this invention. Preferably, the antibodies are generated against stanniocalcin. Such a panel of antibodies may be used as a reliable diagnostic probe for cancer. The assay of the present invention comprises contacting a biopsy sample containing cells, for example, lung cells, with a panel of antibodies to one or more of the encoded products to determine the presence or absence of the marker polypeptides.

[144] The diagnostic methods of the subject invention may also be employed as follow-up to treatment, for example, quantitation of the level of marker polypeptides may be indicative of the effectiveness of current or previously employed cancer therapies as well as the effect of these therapies upon patient prognosis.

[145] In addition, the marker nucleic acids or marker polypeptides may be utilized as part of a diagnostic panel for initial detection, follow-up screening, detection of reoccurrence, and post-treatment monitoring for chemotherapy or surgical treatment.

[146] Accordingly, the present invention makes available diagnostic assays and reagents for detecting gain and/or loss of marker polypeptides from a cell in order to aid in the diagnosis and phenotyping of proliferative disorders arising from, for example, tumorigenic transformation of cells.

[147] The diagnostic assays described above may be adapted to be used as prognostic assays, as well. Such an application takes advantage of the sensitivity of the assays of the invention to events which take place at characteristic stages in the progression of a tumor. For example, a given marker gene may be up- or down-regulated at a very early stage, perhaps before the cell is irreversibly committed to developing into a malignancy, while another marker gene may be characteristically up- or down-regulated only at a much later stage. Such a method could involve the steps of contacting the mRNA of a test cell with a nucleic acid probe derived from a given marker nucleic acid which is expressed at different characteristic levels in cancerous or precancerous cells at different stages of tumor progression, and determining the approximate amount of hybridization of the probe to the mRNA of the cell, such amount being an indication of the level of expression of the gene in the cell, and thus an indication of the stage of tumor progression of the cell; alternatively, the assay may be carried out with an antibody specific for the gene product of the given marker nucleic acid, contacted with the proteins of the test cell. A battery of such tests will disclose not only the existence and location of a tumor, but also will allow the clinician to select the mode of treatment most appropriate for the tumor, and to predict the likelihood of success of that treatment.

[148] The methods of the invention may also be used to follow the clinical course of a tumor. For example, the assay of the invention may be applied to a tissue sample from a patient; following treatment of the patient for the cancer, another tissue sample is taken and the test repeated. Successful treatment will result in either removal of all cells which demonstrate differential expression characteristic of the cancerous or precancerous cells, or a substantial increase in expression of the gene in those cells, perhaps approaching or even surpassing normal levels.

[149] In yet another embodiment, the invention provides methods for determining whether a subject is at risk for developing a disease, such as a predisposition to develop cancer, associated with aberrant activity of a polypeptide, preferably, stanniocalcin, wherein the aberrant activity of the polypeptide is characterized by detecting the presence or absence of a genetic lesion characterized by at least one of (a) an alteration affecting the integrity of a gene encoding a marker polypeptides, or (b) the mis-expression of the encoding nucleic acid. To illustrate, such genetic lesions may be detected by ascertaining the existence of at least one of (i) a deletion of one or more nucleotides from the nucleic acid sequence, (ii) an addition of one or more nucleotides to the nucleic acid sequence, (iii) a substitution of one or more nucleotides of the nucleic acid sequence,

(iv) a gross chromosomal rearrangement of the nucleic acid sequence, (v) a gross alteration in the level of a messenger RNA transcript of the nucleic acid sequence, (vi) aberrant modification of the nucleic acid sequence, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene, (viii) a non-wild type level of the marker polypeptide, (ix) allelic loss of the gene, and/or (x) inappropriate post-translational modification of the marker polypeptide.

[150] The present invention provides assay techniques for detecting lesions in the encoding nucleic acid sequence. These methods include, but are not limited to, methods involving sequence analysis, Southern blot hybridization, restriction enzyme site mapping, and methods involving detection of absence of nucleotide pairing between the nucleic acid to be analyzed and a probe.

[151] Specific diseases or disorders, for example, genetic diseases or disorders, are associated with specific allelic variants of polymorphic regions of certain genes, which do not necessarily encode a mutated protein. Thus, the presence of a specific allelic variant of a polymorphic region of a gene in a subject may render the subject susceptible to developing a specific disease or disorder. Polymorphic regions in genes, may be identified, by determining the nucleotide sequence of genes in populations of individuals. If a polymorphic region is identified, then the link with a specific disease may be determined by studying specific populations of individuals, for example, individuals which developed a specific disease, such as cancer. A polymorphic region may be located in any region of a gene, for example, exons, in coding or non-coding regions of exons, introns, and promoter region.

[152] In an exemplary embodiment, there is provided a nucleic acid composition comprising a nucleic acid probe including a region of nucleotide sequence which is capable of hybridizing to a sense or antisense sequence of a gene or naturally occurring mutants thereof, or 5' or 3' flanking sequences or intronic sequences naturally associated with the subject genes or naturally occurring mutants thereof. The nucleic acid of a cell is rendered accessible for hybridization, the probe is contacted with the nucleic acid of the sample, and the hybridization of the probe to the sample nucleic acid is detected. Such techniques may be used to detect lesions or allelic variants at either the genomic or mRNA level, including deletions, substitutions, etc., as well as to determine mRNA transcript levels.

[153] Another example of a detection method is allele specific hybridization using probes overlapping the mutation or polymorphic site and having, for example, about 5, 10, 20, 25, or 30 nucleotides around the mutation or polymorphic region. In a preferred embodiment of the invention, several probes capable of hybridizing specifically to allelic variants are attached to a solid phase support, for example, a "chip." Mutation detection analysis using these chips comprising oligonucleotides, also termed "DNA probe arrays" is described, for example, by

Cronin, et al., (Human Mutation 7:244, 1996). In one embodiment, a chip may comprise all the allelic variants of at least one polymorphic region of a gene. The solid phase support is then contacted with a test nucleic acid and hybridization to the specific probes is detected. Accordingly, the identity of numerous allelic variants of one or more genes may be identified in a simple hybridization experiment.

[154] In certain embodiments, detection of the lesion comprises utilizing the probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligase chain reaction (LCR) (*see, e.g.*, Landegran, et al., Science 241:1077-1080, 1988; Nakazaw, et al., Proc. Natl. Acad. Sci. USA 91:360-364, 1994), the latter of which can be particularly useful for detecting point mutations in the gene (*see, e.g.*, Abravaya, et al., Nuc. Acid Res. 23:675-682, 1995). In an illustrative embodiment, the method includes the steps of (i) collecting a sample of cells from a patient, (ii) isolating nucleic acid (e.g., genomic, mRNA, or both) from the cells of the sample, (iii) contacting the nucleic acid sample with one or more primers which specifically hybridize to a nucleic acid sequence under conditions such that hybridization and amplification of the nucleic acid (if present) occurs, and (iv) detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

[155] Alternative amplification methods include: self sustained sequence replication (Guatelli, et al., Proc. Natl. Acad. Sci. USA 87:1874-1878, 1990), transcriptional amplification system (Kwoh, et al., Proc. Natl. Acad. Sci. USA 86:1173-1177, 1989), Q-Beta Replicase (Lizardi, et al., Bio/Technology 6:1197, 1988), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

Predictive Assays

[156] Laboratory-based assays, which can predict clinical benefit from a given anti-cancer agent, will greatly enhance the clinical management of patients with cancer. In order to assess this effect, a biomarker associated with the anti-cancer agent may be analyzed in a biological sample (e.g., tumor sample, plasma) before, during, and following treatment.

[157] For example, the expression of stanniocalcin is altered by treatment with a VEGFR2 inhibitor in laboratory animals bearing xenografted human tumors. Relative to the group treated with vehicle, expression of stanniocalcin was decreased in the VEGFR2 inhibitor-treated group.

[158] Another approach to monitor treatment is an evaluation of serum proteomic spectra. Specifically, plasma samples may be subjected to mass spectroscopy (e.g., surface-enhanced laser desorption and ionization) and a proteomic spectra may be generated for each patient. A set of spectra, derived from analysis of plasma from patients before and during treatment, may be analyzed by an iterative searching algorithm, which can identify a proteomic pattern that completely discriminates the treated samples from the untreated samples. The resulting pattern may then be used to predict the clinical benefit following treatment.

[159] Global gene expression profiling of biological samples (e.g., tumor biopsy samples, blood samples) and bioinformatics-driven pattern identification may be utilized to predict clinical benefit and sensitivity, as well as development of resistance to an anti-cancer agent. For example, RNA isolated from cells derived from whole blood from patients before and during treatment may be used to generate blood cell gene expression profiles utilizing Affymetrix GeneChip technology and algorithms. These gene expression profiles may then predict the clinical benefit from treatment with a particular anti-cancer agent.

[160] Analysis of the biochemical composition of urine by 1D ¹H-NMR (Nuclear Magnetic Resonance) may also be utilized as a predictive assay. Pattern recognition techniques may be used to evaluate the metabolic response to treatment with an anti-cancer agent and to correlate this response with clinical endpoints. The biochemical or endogenous metabolites excreted in urine have been well-characterized by proton NMR for normal subjects (Zuppi, et al., Clin Chim Acta 265:85-97, 1997). These metabolites (approximately 30-40) represent the by-products of the major metabolic pathways, such as the citric acid and urea cycles. Drug-, disease-, and genetic-stimuli have been shown to produce metabolic-specific changes in baseline urine profiles that are indicative of the timeline and magnitude of the metabolic response to the stimuli. These analyses are multi-variant and therefore use pattern recognition techniques to improve data interpretation. Urinary metabolic profiles may be correlated with clinical endpoints to determine the clinical benefit.

EXAMPLES

[161] The structures, materials, compositions, and methods described herein are intended to be representative examples of the invention, and it will be understood that the scope of the invention is not limited by the scope of the examples. Those skilled in the art will recognize that the invention may be practiced with variations on the disclosed structures, materials, compositions and methods, and such variations are regarded as within the ambit of the invention.

Example 1. Tumor Xenograft Gene Expression Profiling Protocol

A. Tumor implantation and excision

[162] Female nude mice ranging between 11-19 weeks of age, and with an average weight of approximately 18-25 grams were used in these studies. The human breast carcinoma (MDA-MB-231) cancer cell line was grown in tissue culture to approximately 70% confluency. Cells were harvested on the day of implant (5×10^6 cells/mouse), and were suspended in Hanks Balanced Salt Solution from the time of harvest to the time of implant at which time each mouse received a 0.2 ml injection of the cell suspension of the appropriate cell inoculum. The cells were injected subcutaneously in the right flank of each mouse and tumors were monitored for growth. Time of staging (dosing) was determined when tumors reached a size of 75-125 mgs (from Day 5 - Day 9 of implant). Animals were then treated with a VEGFR2 inhibitor. The vehicle used for the VEGFR2 inhibitor is PEG/glycerin (95:5). Oral dosing was at 40 mg/kg once a day for 9 days. On day 9, at 1, 2, 4 and 8 hours after the dose, mice were euthanized and three drug-treated and three vehicle-treated tumors were harvested and snap frozen.

B. RNA extraction and cRNA preparation

[163] Total RNA was extracted from tumor explants using TRIzol reagent (Life Technologies, Rockville, MD) according to a modified vendor protocol which utilizes the RNeasy protocol (Qiagen, Valencia, CA). After homogenization with a Brinkmann Polytron PT10/35 (Brinkmann, Westbury, NY) and phase separation with chloroform, samples were applied to RNeasy columns. RNA samples were treated with DNase I using RNase-free DNase Set (Qiagen, Valencia, CA).

[164] After elution and quantitation with UV spectrophotometry, each sample was reverse transcribed into double-stranded cDNA using the Gibco Superscript II Choice System for RT-PCR according to vendor protocol (Invitrogen, Carlsbad, CA).

C. cDNA preparation for TaqMan Analysis

[165] Each RNA sample was reverse transcribed using the GibcoBRL Superscript II First Strand Synthesis System for RT-PCR according to vendor protocol (Life Technologies, Rockville, MD).

The final concentration of RNA in the reaction mix was 50 ng/μL. Reverse transcription was performed with 50 ng of random hexamers.

D. TaqMan quantitative analysis using fluorescent probes

[166] Since the endothelial cells in the xenograft experiments are derived from mouse, specific primers and probes to mouse stanniocalcin-1 (SEQ ID NO: 5 and 6) and stanniocalcin-2 (SEQ ID NO: 7 and 8) were designed and are listed below:

Mouse stanniocalcin-1

Mouse stanniocalcin-1 forward primer: 5'-(GAACCAGAAAAGCTAGTCAAGTGTGT)-3'
(SEQ ID NO: 9)

Mouse stanniocalcin-1 reverse primer: 5'-(GAGAAAAGAGAAAGAAAGTTTACTGAACT)-3'
(SEQ ID NO: 10)

Mouse stanniocalcin-1 probe:

5'-(FAM)-CAGAAGCCCAAAGTGGCAAATAGCTTATGAGAAT-(TAMRA)-3'
(SEQ ID NO: 11)

Mouse stanniocalcin-2

Mouse stanniocalcin-2 forward primer: 5'-(GTTGTATTGAATCGGCCGTGTA)-3'
(SEQ ID NO: 12)

Mouse stanniocalcin-2 reverse primer: 5'-(CCCCCAACAGACCATACTTAA)-3'
(SEQ ID NO: 13)

Mouse stanniocalcin-2 probe:

5'-(FAM)-CTGTCTTCGGTCTGTGGAGTTAGTTGGTG-(TAMRA)-3' (SEQ ID NO: 14)

Mouse beta2-microglobulin

Mouse beta2-microglobulin forward primer: 5'-(CCGAACATACTGAACTGCTACGTAAC)-3'
(SEQ ID NO: 15)

Mouse beta2-microglobulin reverse primer: 5'-(TTCCCGTTCTTCAGCATTG)-3'
(SEQ ID NO: 16)

Mouse beta2-microglobulin probe:

5'-(VIC)-CAGTTCCACCCGCCTCACATTGAAAT-(TAMRA)-3' (SEQ ID NO: 17)

where FAM = 6-carboxy-fluorescein
and TAMRA = 6-carboxy-tetramethyl-rhodamine.

[167] Quantitation experiments were performed on 25 ng reverse transcribed RNA from each sample. Assay reaction mix was as follows:

| | |
|---|---------------|
| | final |
| TaqMan Universal PCR Master Mix (2x) (PE Applied Biosystems, CA) | 1x |
| PDAR control – 18S RNA (20x) | 1x |
| Forward primer | 300 nM |
| Reverse primer | 300 nM |
| Probe | 200 nM |
| cDNA | 10 ng |
| Water | to 25 μ L |

F. PCR conditions:

[168] Once: 2 minutes at 50°C
 10 minutes at 95°C
 40 cycles: 15 sec. at 95°C
 1 minute at 60°C

[169] The experiment was performed on an ABI Prism 7700 Sequence Detector (PE Applied Biosystems, CA). At the end of the run, fluorescence data acquired during PCR were processed as described in the ABI Prism 7700 user's manual. Fold change was calculated using the delta-delta CT method with normalization to the beta2-microglobulin values. Figure 1 depicts the expression changes of the mouse stanniocalcin-1 and stanniocalcin-2 gene in response to exposure to a VEGFR2 inhibitor. The Y axis depicts the fold change of expression of stanniocalcin-1 and stanniocalcin-2 in the compound-treated, tumor-bearing animals relative to vehicle treated, tumor-bearing animals. The X axis depicts the time, in hours, after the dose on day 9 at which the tumor samples were taken. The data for TaqMan gene expression analysis methods are plotted.

Example 2. In Vitro Endothelial Cell Gene Expression Profiling Protocol

A. Cell line treatment and RNA harvest

[170] Pooled human microvascular endothelial cells (HMVECs) or human umbilical vein endothelial cells (HUVECs) were purchased as 2 T75 flasks (Clonetics, Cambrex Corporation, East Rutherford, NJ). Cells were expanded in full Clonetics growth media (EGF + 5% FCS) on 2% gelatin coated flasks until sufficient numbers were obtained to perform the experiment (4 flasks each at less than 6 passages). Prior to the treatments, cells were washed 2x in PBS and starved overnight in basal media (EBM + 0.2% endotoxin free BSA). The next day, media was

removed and replaced with 25 ml of EBM + BSA. VEGFR2 inhibitor (drug) stock was made in DMSO and added to a final concentration of 100 nM in 0.1% DMSO. Heparin was used at 1.5 U/ml final concentration. VEGF final concentration was 10 ng/ml. Drug/DMSO was added for 30 minutes prior to adding VEGF/Heparin for 2 hours. The VEGF/Heparin was preincubated on ice for 5 minutes prior to addition to the flasks. After 2 hours, the media was removed, cells were washed 2x in PBS, trypsinized, washed an additional 1x in PBS and then lysed in Qiagen RLT buffer, and stored at -80°C . RNA was subsequently isolated via Qiagen midi spin kits and quantitated by $\text{OD}_{260/280}$ and gel visualization and/or Agilent bioanalyzer.

B. Affymetrix Analysis

[171] Samples were organically extracted and ethanol precipitated. Approximately 1 μg cDNA was then used in an *in vitro* transcription reaction incorporating biotinylated nucleotides using an RNA labeling kit (Enzo Diagnostics, NY). The resulting cRNA was put through RNeasy clean-up protocol, and then quantified using UV spectrophotometry. The cRNA (15 μg) was fragmented in the presence of MgOAc and KOAc at 94°C . Fragmented RNA (10 μg) was loaded onto each array, one cRNA sample per array. Arrays were hybridized for 16 hours at 45°C rotating at 60 rpm in an Affymetrix GeneChip Hybridization Oven 640.

C. Microarray Suite 5.0 analysis

[172] Following hybridization, arrays were stained with Phycoerythrin-conjugated Streptavidin, placed in an Agilent GeneArray Scanner and then exposed to a 488 nm laser, causing excitation of the phycoerythrin. The Microarray Suite 5.0 software digitally converts the intensity of light given off by the array into a numeric value indicative of levels of gene expression. Because each array represented a single animal sample, treated animals were compared to the vehicle animals and relative fold changes of genes were obtained. Those genes increased or decreased by at least 2-fold change were considered significant and chosen for further analysis.

D. TaqMan Analysis

[173] cDNA was synthesized from the isolated RNA using Gibco cDNA synthesis kit with random hexamer priming and Superscript polymerase including a minus RT control. PCR primers were designed by Primer Express. The stanniocalcin primers are:

Forward primer: 5'-(TGA AGA CAC AGT CAG CAC AAT CA)-3' (SEQ ID NO: 18) and

Reverse primer: 5'-(GGA AGA GGC TGG CCA TGT T)-3' (SEQ ID NO: 19).

[174] A master mix of the primers at 50 μM each was prepared. The samples were analyzed by standard PCR conditions on an ABI PRISM 7700 Sequence Detector using SYBR green probes. β -actin was used as controls for loading normalization.

[175] Figure 2A shows that human stanniocalcin-1 expression in HMVECs after treatment with VEGF is induced nearly 20-fold. When HMVECs are treated with both VEGF and a VEGFR2 inhibitor, stanniocalcin expression is reduced to the same level as when the cells are treated with the inhibitor alone (i.e., without VEGF addition).

[176] Figure 2B demonstrates a similar experiment that was designed as a time course after co-addition of VEGF and inhibitor. Both Affymetrix and TaqMan data are plotted. Fold change is the difference in stanniocalcin expression when the cells are exposed to the inhibitor +/- VEGF. The VEGFR2 inhibitor decreases stanniocalcin expression that is induced by VEGF.

[177] Figure 3A is a similar time course as described above for Figure 2B but rather using HUVECs. Only TaqMan data is shown. Figure 3B is a second experiment similar to that depicted in Figure 3A, although both Affymetrix and TaqMan data are plotted.

We claim:

1. A method to monitor the response of a patient being treated for cancer by administering a anti-cancer agent, comprising the steps of:
 - (a) determining the level of expression of one or more one biomarker(s) in a first biological sample taken from the patient prior to treatment with the anti-cancer agent;
 - (b) determining the level of expression of the biomarker in at least a second biological sample taken from the patient subsequent to the initial treatment with the anti-cancer agent; and
 - (c) comparing the level of expression of the biomarker in the second biological sample with the level of expression of the biomarker in the first biological sample;wherein a change in the level of expression of the biomarker in the second biological sample compared to the level of expression of biomarker in the first biological sample indicates that the effectiveness of the treatment with the anti-cancer agent agent.
2. The method of claim 1, wherein said anti-cancer agent is a VEGFR2 inhibitor.
3. The method of claim 1, wherein said biomarker is stanniocalcin.
4. The method of claim 3, wherein the nucleic acid sequence for stanniocalcin is SEQ ID NO: 1 or 3.
5. The method of claim 3, wherein the amino acid sequence for stanniocalcin is SEQ ID NO: 2 or 4.
6. A method for identifying a compound useful for the treatment of cancer comprising the steps of:
 - (a) analyzing the level of expression of one or more genes in a cell or tissue sample prior to treatment with the compound;
 - (b) analyzing the level of expression of one or more genes in a cell or tissue sample subsequent to treatment with the compound;wherein a variation in the expression level of the gene is indicative of drug efficacy.
7. The method of claim 6, wherein the gene is stanniocalcin.
8. The method of claim 7, wherein the nucleic acid sequence for stanniocalcin is SEQ ID NO: 1 or 3.

9. The method of claim 7, wherein the amino acid sequence for stanniocalcin is SEQ ID NO: 2 or 4.
10. A method for identifying a compound useful for the treatment of cancer comprising the steps of:
 - (a) analyzing the level of expression of one or more polypeptides in a cell or tissue sample prior to treatment with the compound;
 - (b) analyzing the level of expression of one or more polypeptides in a cell or tissue sample subsequent to treatment with the compound;wherein a variation in the expression level of the polypeptides is indicative of drug efficacy.
11. The method of claim 10, wherein the polypeptide is stanniocalcin.
12. The method of claim 10, wherein the nucleic acid sequence for stanniocalcin is SEQ ID NO: 1 or 3.
13. The method of claim 10, wherein the amino acid sequence for stanniocalcin is SEQ ID NO: 2 or 4.
14. A method to predict the response of a patient to an anti-cancer agent, comprising the steps of:
 - (a) determining the level of expression of one or more biomarker(s) in a first biological sample taken from the patient prior to treatment with the anti-cancer agent;
 - (b) determining the level of expression of one or more biomarker(s) in at least a second biological sample taken from the patient, wherein the second biological sample is exposed to the anti-cancer agent; and
 - (c) comparing the level of expression of one or more biomarker(s) in the second biological sample with the level of expression of one or more one biomarker(s) in the first biological sample;wherein a change in the level of expression of one or more biomarker(s) in the second biological sample compared to the level of expression of one or more biomarker(s) in the first biological sample predicts the response of the patient to an anti-cancer agent.
15. The method of claim 14, wherein the anti-cancer agent is an VEGFR2 inhibitor.
16. The method of claim 14, wherein the biomarker is stanniocalcin.

17. The method of claim 16, wherein the nucleic acid sequence for stanniocalcin is SEQ ID NO: 1 or 3.
18. The method of claim 16, wherein the amino acid sequence for stanniocalcin is SEQ ID NO: 2 or 4.
19. A kit comprising a primer or probe for measuring the expression level of a nucleic acid sequence wherein the primer or probe comprises at least 15 nucleotides.
20. The kit of claim 19, wherein the nucleic acid sequence encodes stanniocalcin.
21. The kit of claim 20, wherein the nucleic acid sequence for stanniocalcin is SEQ ID NO: 1 or 3.
22. The kit of claim 19, further comprising one or more components selected from solutions for suspending or fixing tissue or cell samples, solutions for lysing cells, hybridization solutions, solutions for the isolation of nucleic acids, control samples, and instructions for using the kit.
23. A kit comprising an antibody specific for a protein.
24. The kit of claim 23, wherein the antibody is specific for stanniocalcin.
25. The kit of claim 24, wherein the amino acid sequence for stanniocalcin is SEQ ID NO: 2 or 4.
26. The kit of claim 20, further comprising solutions for suspending or fixing tissue or cell samples, solutions for lysing cells, substrates, buffer reagents, blocker reagents, blotting reagents, control samples, and instructions for using the kit.




FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 3A




FIGURE 3B

SEQUENCE LISTING

<110> Bayer Pharmaceuticals Corporation
 Kasper, James
 Pauloski, Nicole
 Taylor, Ian
 Elting, James
 Sarr, Timothy

<120> Methods for Prediction and Prognosis of Cancer, and Monitoring
 Cancer Therapy

<130> 5184

<150> US 60/529,438

<151> 2003-12-12

<160> 19

<170> PatentIn version 3.3

<210> 1

<211> 3901

<212> DNA

<213> Homo sapiens

<400> 1
 cagtttgc aaagccagagg tgcaagaagc agcgactgca gcagcagcag cagcagcggc 60
 ggtggcagca gcagcagcag cggcggcagc agcagcagca gcggaggcac cgggtggcagc 120
 agcagcatca ccagcaacaa caacaaaaaa aaatcctcat caaatcctca cctaagcttt 180
 cagtgtatcc agatccacat cttcactcaa gccaggagag ggaaagagga aaggggggca 240
 ggaaaaaaaaaaa aaaaccaac aacttagcgg aaacttctca gagaatgctc caaaactcag 300
 cagtgcttct ggtgctgggtg atcagtgctt ctgcaacca tgaggcggag cagaatgact 360
 ctgtgagccc caggaaatcc cgagtggcgg ctcaaaactc agctgaagtg gttcgttgcc 420
 tcaacagtg tctacaggtc ggctgccccg cttttgcatg cctggaaaac tccacctgtg 480
 acacagatgg gatgtatgac atctgtaa atccttctgta cagcgctgct aaatttgaca 540
 ctcagggaaa agcattcgtc aaagagagct taaaatgcat cgccaacggg gtcacctcca 600
 aggtcttctc cgccattcgg aggtgctcca ctttccaaag gatgattgct gaggtgcagg 660
 aagagtgcta cagcaagctg aatgtgtgca gcatcgccaa gcggaaccct gaagccatca 720
 ctgaggtcgt ccagctgccc aatcacttct ccaacagata ctataacaga cttgtccgaa 780
 jcttgctgga atgtgatgaa gacacagtca gcacaatcag agacagcctg atggagaaaa 840
 ttgggcctaa catggccagc ctcttcaca tcttgagac agaccactgt gcccaaacac 900
 acccagagc tgacttcaac aggagacgca ccaatgagcc gcagaagctg aaagtcctcc 960
 :caggaacct ccgaggtgag gaggactctc cctcccacat caaacgcaca tcccatgaga 1020
 jtgcataacc agggagaggt tattcacaac ctcaccaaac tagtatcatt ttaggggtgt 1080
 :gacacacca attttgagtg tactgtgcct ggtttgattt ttttaaagta gttcctattt 1140
 :ctatcccc ttaaagaaaa ttgcatgaaa ctaggcttct gtaatcaata tcccaacatt 1200
 :tgcaatggc agcattcca ccaacaaat ccatgtgatc attctgcctc tcctcaggag 1260

aaagtaccct cttttacca cttcctctgc catgtctttt cccctgctcc cctgagacca 1320
cccccaaca caaacattc atgtaactct ccagccattg taatttgaag atgtggatcc 1380
ctttagaacg gttgc'cccag tagagttagc tgataaggaa actttattta aatgcatgtc 1440
ttaaattgctc ataaagatgt taaatggaat tcgtgttatg aatctgtgct ggccatggac 1500
gaatatgaat gtcacatttg aattcttgat ctctaattgag ctagtgtctt atggctcttga 1560
tcctccaatg tctaattttc tttccgacac atttaccaa ttgcttgagc ctggctgtcc 1620
aaccagactt tgagcctgca tcttcttgca tctaataaaa aacaaaaagc taacatcttt 1680
acgtactgta actgctcaga gctttaaag tatctttaac aattgtctta aaaccagaga 1740
atcttaaggt ctaactgtgg aatataaata gctgaaaact aatgtactgt acataaattc 1800
cagaggactc tgcttaaaca aagcagtata taataacttt attgcatata gatttagttt 1860
tgtaacttag ctttattttt cttttcctgg gaatggaata actatctcac ttccagatat 1920
ccacataaat gctccttgty gcctttttta taactaagg ggtagaagta gttttaattc 1980
aacatcaaaa cttaagatgg gcctgtatga gacaggaaaa accaacaggt ttatctgaag 2040
gaccccaggt aagatgttaa tctcccagcc cacctcaacc cagaggctac tcttgactta 2100
gacctatact gaaagatctc tgtcacatcc aactggaat tccaggaacc aaaaagagca 2160
tcctatggg cttggaccac ttacagtgtg ataaggccta ctatacatta ggaagtggta 2220
gttctttact cgtccccttt catcggtgcc tggactctg gcaaatgatg atgggggtggg 2280
agactttcca ttaaataaat caggaatgag tcaatcagcc tttaggtctt tagtccgggg 2340
gacttggggc tgagagagta taaataacc tgggctgtcc agccttaata gacttctctt 2400
acattttcgt cctgtagcac gctgcctgcc aaagtagtcc tggcagctgg accatctctg 2460
taggatcgta aaaaaataga aaaaaagaaa aaaaaagaa agaaagaggg aaaaagagct 2520
ggtggtttga tcatttctgc catgatgttt acaagatggc gaccaccaa gtcaaacgac 2580
taacctatct atgaacaaca gtagtttctc agggctactg tccttgaacc caacagtccc 2640
ttatgagcgt cactgcccac caaaggtaaa tgtcaagaga ggaagagagg gaggaggggt 2700
aggactgcag gggccactcc aaactcgtt aggtagaaac tattgggtgct cgactctcac 2760
taggctaaac tcaagatttg accaaatcga gtgatagggg tcctgggtggg aggagagagg 2820
gcacatctcc agaaaaatga aaagcaatac aactttacca taaagccttt aaaaccagta 2880
acgtgctgct caaggaccaa gagcaattgc agcagacca gcagcagcag cagcagcaca 2940
aacattgctg cttttgtccc cacacagcct ctaagcgtgc tgacatcaga ttgttaaggg 3000
catttttata ctcagaactg tcccatcccc aggtcccaa acttatggac actgccttag 3060
cctcttggaa atcaggtaga ccatattcta agttagactc ttcccctccc tcccacactt 3120
cccaccccca ggcaaggctg acttctctga atcagaaaag ctattaaagt ttgtgtgttg 3180
tgtccatttt gcaaacccea ctaagccagg accccaatgc gacaagtagt tcatgagtat 3240
tcctagcaaa tttctctctt tcttcagttc agtagatttc cttttttctt ttcttttttt 3300

```

tttttttttt tttttggctg tgacctcttc aaaccgtggt accccccctt ttctccccac 3360
gatgatattct atatattgat ctacaataca tatattctaca catacagaaa gaagcagttc 3420
tcacatgttg ctagtttttt gcttctcttt cccccaccct actccctcca attccccctt 3480
taaacttcca aagcttcgct ttgtgtttgc tgcagagtga ttcgggggct gacctagacc 3540
agtttgcattg attcttctct tgtgatttgg ttgcacttta gacatttttg tgccattata 3600
tttgcattat gtatttataa tttaaattgat atttaggttt ttggctgagt actggaataa 3660
acagtgagca tatctggtat atgtcattat ttattgttaa attacatttt ttaagctcca 3720
tgtgcatata aaggttatga aacatatcat ggtaatgaca gatgcaagtt attttatttg 3780
cttatttttt ataattaaag atgccatagc ataatatgaa gcctttgggtg aattccttct 3840
aagataaaaa taataataaa gtgttacggt ttattgggtt caaaaaaaaa aaaaaaaaaa 3900
a 3901

```

```

<210> 2
<211> 247
<212> PRT
<213> Homo sapiens

```

<400> 2

```

Met Leu Gln Asn Ser Ala Val Leu Leu Val Leu Val Ile Ser Ala Ser
1 5 10 15
Ala Thr His Glu Ala Glu Gln Asn Asp Ser Val Ser Pro Arg Lys Ser
20 25 30
Arg Val Ala Ala Gln Asn Ser Ala Glu Val Val Arg Cys Leu Asn Ser
35 40 45
Ala Leu Gln Val Gly Cys Gly Ala Phe Ala Cys Leu Glu Asn Ser Thr
50 55 60
Cys Asp Thr Asp Gly Met Tyr Asp Ile Cys Lys Ser Phe Leu Tyr Ser
65 70 75 80
Ala Ala Lys Phe Asp Thr Gln Gly Lys Ala Phe Val Lys Glu Ser Leu
85 90 95
Lys Cys Ile Ala Asn Gly Val Thr Ser Lys Val Phe Leu Ala Ile Arg
100 105 110
Arg Cys Ser Thr Phe Gln Arg Met Ile Ala Glu Val Gln Glu Glu Cys
115 120 125
Tyr Ser Lys Leu Asn Val Cys Ser Ile Ala Lys Arg Asn Pro Glu Ala
130 135 140
Ile Thr Glu Val Val Gln Leu Pro Asn His Phe Ser Asn Arg Tyr Tyr

```


ggctcagggg ccttccggaa gcagcgagtg ggaagacgaa cagtctgagt attctgatat 1140
 ccggagggtga aatgaaaggc ctggccacga aatctttcct ccacgccgtc cattttctta 1200
 tctatggaca ttccaaaaca ttaccatta gagagggggg atgtcacacg caggattctg 1260
 tggggactgt ggacttcatc gaggtgtgtg ttcgcggaac ggacaggtga gatggagacc 1320
 cctggggccg tggggctca ggggtgcctg gtgaattctg cacttacacg tactcaaggg 1380
 agcgcgcccg cgttatcctc gtaccttgt cttctttcca tctgtggagt cagtgggtgt 1440
 cggccgctct gttgtggggg aggtgaacca gggaggggca gggcaaggca gggccccag 1500
 agctgggcca cacagtgggt gctgggcctc gccccgaagc ttctggtgca gcagcctctg 1560
 gtgctgtctc cgcggaagtc agggcggctg gattccagga caggagtga tgtaaaaata 1620
 aatatcgctt agaatgcagg agaaggggtg agaggaggca ggggccgagg gggtgcttg 1680
 tgccaaactg aaattcagtt tcttgtgtgg ggccttgcgg ttcagagctc ttggcgaggg 1740
 tggagggagg agtgtcattt ctatgtgtaa tttctgagcc attgtactgt ctgggctggg 1800
 ggggacactg tccaagggag tggcccctat gagtttatat ttaaccact gcttcaaact 1860
 tcgatttcac ttttttatt tatccagtta tatctacata tctgtcatct aaataaatgg 1920
 ctttcaaaca aaaaaaaaa aaaaaaa 1947

<210> 4
 <211> 302
 <212> PRT
 <213> Homo sapiens

<400> 4

Met Cys Ala Glu Arg Leu Gly Gln Phe Met Thr Leu Ala Leu Val Leu
 1 5 10 15

Ala Thr Phe Asp Pro Ala Arg Gly Thr Asp Ala Thr Asn Pro Pro Glu
 20 25 30

Gly Pro Gln Asp Arg Ser Ser Gln Gln Lys Gly Arg Leu Ser Leu Gln
 35 40 45

Asn Thr Ala Glu Ile Gln His Cys Leu Val Asn Ala Gly Asp Val Gly
 50 55 60

Lys Gly Val Phe Glu Cys Phe Glu Asn Asn Ser Cys Glu Ile Arg Gly
 65 70 75 80

Leu His Gly Ile Cys Met Thr Phe Leu His Asn Ala Gly Lys Phe Asp
 85 90 95

Ile Gln Gly Lys Ser Phe Ile Lys Asp Ala Leu Lys Cys Lys Ala His
 100 105 110

Ile Leu Arg His Arg Phe Gly Cys Ile Ser Arg Lys Cys Pro Ala Ile

115 120 125

Arg Glu Met Val Ser Gln Leu Gln Arg Glu Cys Tyr Leu Lys His Asp
 130 135 140

Leu Cys Ala Ala Ala Gln Glu Asn Thr Arg Val Ile Val Glu Met Ile
 145 150 155 160

His Phe Lys Asp Leu Leu Leu His Glu Pro Tyr Val Asp Leu Val Asn
 165 170 175

Leu Leu Leu Thr Cys Gly Glu Glu Val Lys Glu Ala Ile Thr His Ser
 180 185 190

Val Gln Val Gln Cys Glu Gln Asn Trp Gly Ser Leu Cys Ser Ile Leu
 195 200 205

Ser Phe Cys Thr Ser Ala Ile Gln Lys Pro Pro Thr Ala Pro Pro Glu
 210 215 220

Arg Gln Pro Gln Val Asp Arg Thr Lys Leu Ser Arg Ala His His Gly
 225 230 235 240

Glu Ala Gly His His Leu Pro Glu Pro Ser Ser Arg Glu Thr Gly Arg
 245 250 255

Gly Ala Lys Gly Glu Arg Gly Ser Lys Ser His Pro Asn Ala His Ala
 260 265 270

Arg Gly Arg Val Gly Gly Leu Gly Ala Gln Gly Pro Ser Gly Ser Ser
 275 280 285

Glu Trp Glu Asp Glu Gln Ser Glu Tyr Ser Asp Ile Arg Arg
 290 295 300

<210> 5
 <211> 2341
 <212> DNA
 <213> Mus musculus

<400> 5
 ccacgcgtcc gctaagcttt cagtatatcc agatccacat cttcactcaa gccgggagag 60
 ggaaagagga aaggggggga ggaaaaaaaa aagccaacaa cttagcggaa acttctcaga 120
 gaatgctcca aaactcagca gtgattctgg cgctggtcat cagtgcagct gcagcgcacg 180
 aggcggaaca aaatgattct gtgagcccca gaaaatccc ggtggcggct caaaattcag 240
 ctgaagtggg tcgctgcctc aacagtgcc tgcaggttgg ctgcggggct tttgcatgcc 300
 tggaaaactc cacatgtgac acagatggga tgtacgacat ttgtaaatac ttcttgatac 360
 gtgctgctaa atttgacact cagggaaaag catttgctca agagagctta aagtgcacgc 420
 ccaatgggat cacctccaag gtattccttg ccattcggag gtgttcgact ttccagagga 480

```

tgatcgccga ggtgcaggag gactgctaca gcaagcttaa cgtttgcagc atcgccaagc 540
gcaacccgga agccatcact gaagtcatac agctgcccaa tcacttctcc aacagatact 600
acaacagact tgtccgaagc cttctggaat gtgatgaaga cacggtcagt acaatcagag 660
acagcctgat ggagaagatc gggcccaaca tggccagcct cttccacatc ctgcagacag 720
accactgtgc ccagacacac cccagagctg acttcaatag gaggcgcaca aatgagccac 780
agaagctgaa agtcctcctc aggaacctcc gaggtgaggg ggactctccc tcacacatca 840
aacgcacctc ccaagagagt gcgtaagcag ggagaggtat tcacagcctc accaaactaa 900
tagcatttta ggggtgttga cacaccaact ttgagtgtac tgtgcctggg ttgatttttt 960
ttaagtagta cctattttct atccccctgt taaagaaaaa ttgcatgaaa ctaggcttcc 1020
ataatcaata tccaacatt ctgcaatgac agcattctta ccaacagaat acatgtgtgg 1080
tcattctgcc tctcctcaag agagaatgta ccctcttcca tccccctct ctctgaattc 1140
ttttccaga tccctatcta ctctccgcaa acacaaacca ttcatgtaac taccagtca 1200
ttgtaatctg aaaatgtaga tccctttaga atggtcacct ggtagagtta gccaatataa 1260
aacaacttta tttaaagca tgtcttaaat gctcataaat atgttaaag gaattcgtgt 1320
tatgaatctg tgctggccat ggacgaatat gaatgtcatg tttgaattct tgatctctaa 1380
cgagtcttat ggtctctatc ctccaatgtc taatttcctt tctgacatat ttaccaaatt 1440
gctcaaacct ggttctccaa ccagactttg agctagcatc ttcttgcac taatgaaaaa 1500
caaaaaagct aacatcttta tgtactgtaa ctgctcagag ctttaaaggt atctttaaca 1560
attgtcttaa aaaacggaga atcttaaggt ctaactgtgg aatataaata gctgaaaact 1620
attgtactgt acataaattc cagaggactc tgcttaacag agcagtctat aataacttta 1680
ttgcatatag atttagtttt gtaccttagc tttattttcc ttttctggg aatggaataa 1740
ctatctcact tccagatata cacattcatg ctcttgtgg cttttttat aactaagggg 1800
gtagaagtag ttttaactca acatcagaac ttaagatggg cctatacttg acaggaaaac 1860
ccaacaggtt atctgaagga cccaggtaa gacgttaatc tcccagccca cctcaaccgg 1920
gaggctacgt ttgacttaga tgtatcctga aacagctctg tcacatccaa ctgggaataa 1980
caagaatcaa aaagaccatc ctttgggct tggaccactt ggtgtgacaa ggcctactat 2040
ccccttggaa gtggcagttc ttggctcatc gccttccatc agtgcctggc actctggtaa 2100
atgatggagt gggatattgt tccactaagc caatcaggaa tgagtcaatc agccttggg 2160
tctttagtcc gggaaaacttg ggcttaaggg ggtatgaata accctgggct gtccagcctt 2220
aatagactcc tcttacatct tttgtcctgt aacatgctgc ctgccaaggt agtcctggca 2280
jctggaccat ctctgtagga tcttataaaa aaaagaaaaa aagaaaaaaa aaaaaaaaaa 2340
1 2341

```

:210> 6
:211> 247

<212> PRT
 <213> Mus musculus

<400> 6

Met Leu Gln Asn Ser Ala Val Ile Leu Ala Leu Val Ile Ser Ala Ala
 1 5 10 15
 Ala Ala His Glu Ala Glu Gln Asn Asp Ser Val Ser Pro Arg Lys Ser
 20 25 30
 Arg Val Ala Ala Gln Asn Ser Ala Glu Val Val Arg Cys Leu Asn Ser
 35 40 45
 Ala Leu Gln Val Gly Cys Gly Ala Phe Ala Cys Leu Glu Asn Ser Thr
 50 55 60
 Cys Asp Thr Asp Gly Met Tyr Asp Ile Cys Lys Ser Phe Leu Tyr Ser
 65 70 75 80
 Ala Ala Lys Phe Asp Thr Gln Gly Lys Ala Phe Val Lys Glu Ser Leu
 85 90 95
 Lys Cys Ile Ala Asn Gly Ile Thr Ser Lys Val Phe Leu Ala Ile Arg
 100 105 110
 Arg Cys Ser Thr Phe Gln Arg Met Ile Ala Glu Val Gln Glu Asp Cys
 115 120 125
 Tyr Ser Lys Leu Asn Val Cys Ser Ile Ala Lys Arg Asn Pro Glu Ala
 130 135 140
 Ile Thr Glu Val Ile Gln Leu Pro Asn His Phe Ser Asn Arg Tyr Tyr
 145 150 155 160
 Asn Arg Leu Val Arg Ser Leu Leu Glu Cys Asp Glu Asp Thr Val Ser
 165 170 175
 Thr Ile Arg Asp Ser Leu Met Glu Lys Ile Gly Pro Asn Met Ala Ser
 180 185 190
 Leu Phe His Ile Leu Gln Thr Asp His Cys Ala Gln Thr His Pro Arg
 195 200 205
 Ala Asp Phe Asn Arg Arg Arg Thr Asn Glu Pro Gln Lys Leu Lys Val
 210 215 220
 Leu Leu Arg Asn Leu Arg Gly Glu Gly Asp Ser Pro Ser His Ile Lys
 225 230 235 240
 Arg Thr Ser Gln Glu Ser Ala
 245

<210> 7
 <211> 1793
 <212> DNA
 <213> Mus musculus

<400> 7
 ggctaacggc ctggtcacat gctctccaga gagctacggg agggcgctgg gtaacctcta 60
 tccgagccgc ggcgaggagg aggggaagggg ccagcgagga ggaagagtgg gaggaggggg 120
 aagcggcggg ggaggaagag gaggaggagg ggcgcacaaa gaatccaggt ctccaggcgg 180
 gagggtgata cccagaacca tgtgtgcgga gcggtggggc cagtttgtga ccctggcttt 240
 ggtgtttgcc accttgacc cggcgcaggg gacggactcc acgaaccctc cggaaggtcc 300
 ccaagacagg agctcgcagc agaaaggccg tctgtccctg cagaacacag cggagatcca 360
 gcactgtttg gtcaatgccg gggacgtggg ctgtggtgtg tttgagtgtt tcgagaacaa 420
 ctcttgtgaa atccagggtt tacatgggat ttgcatgacg tttctgcaca acgctggaaa 480
 attcgatgcc cagggaaagt cattcatcaa ggatgccctg aggtgcaagg cccatgcctt 540
 gcgtcataaa tttggctgca tcagcaggaa gtgtccagca attagggaaa tggttttcca 600
 gttgcagagg gaatgctatc tgaagcatga cctgtgctcc gcagcccagg agaacgtcgg 660
 tgtgattgtg gagatgattc atttcaagga tctcctgctg catgagccct atgtggacct 720
 tgtgaacctg ctgctgacct gcggggaaga tgtgaaggag gcagtcaccc gcagcgtcca 780
 ggctcagtgt gaacagagct ggggaggcct ctgctccatc ctgagtttct gcacctcaa 840
 tatacagaga cctcccacgg cagccccaga gcatcagccc ctggcagaca gggctcagct 900
 ctccaggcct caccaccggg acacagacca tcacctaca gccaacagag gtgccaaggg 960
 tgagcgaggg agcaaaagcc acccgaatgc ccatgctcga ggcagaaccg gtggccagag 1020
 cgctcagggg ccctctggaa gcagtgagtg ggaggatgaa cagtctgagt attccgacat 1080
 ccggagggtga aatgaaaacc gggccatgaa agctttcctc caggctgtcc attttcttat 1140
 ctatggacat tccaaaacat ttacattaa gaggggggat gtcacacgct ggatgtgtgc 1200
 aaattgtgga cttcgtgcag gtgtgtgaac aggtgagatg aagattcccg ggcagcaagg 1260
 tctcgagtgc ctggtgggtt ggcacctgtg taagcttatt ggcgggagtg ttgtattgaa 1320
 tcggccgtgt aactgtctct tcggtctgtg gagttagttg gtggcttaag tatggtctgt 1380
 tggggggagg tcagccgggg aggggaagggg ccacaggtgg gtggtaaacc ctccccaca 1440
 jttcccagta ctgtctgcac agagcagggg ctgggttctg gggtagggct gagtggagat 1500
 acagctgaca aggcagagag agcagagagg aggaagggct tagccccact cagtcccaaa 1560
 ccggaagttt agtgtcgtgc atgggatcta gtgtttcaga gctgctggag gggacatgga 1620
 tgggtacattt tctgtgtgtc atttctgagc cattgttctg tctgggggac actgaaggag 1680
 cggcctgtt tgtttatttt tgaccactgt ttcaagtctc cattttactt tttttttttt 1740
 caaatcaact gacatctatg tgtctgtcat ctaaataaat ggctttcaaa cca 1793

<210> 8
 <211> 296
 <212> PRT
 <213> Mus musculus

<400> 8

Met Cys Ala Glu Arg Leu Gly Gln Phe Val Thr Leu Ala Leu Val Phe
 1 5 10 15

Ala Thr Leu Asp Pro Ala Gln Gly Thr Asp Ser Thr Asn Pro Pro Glu
 20 25 30

Gly Pro Gln Asp Arg Ser Ser Gln Gln Lys Gly Arg Leu Ser Leu Gln
 35 40 45

Asn Thr Ala Glu Ile Gln His Cys Leu Val Asn Ala Gly Asp Val Gly
 50 55 60

Cys Gly Val Phe Glu Cys Phe Glu Asn Asn Ser Cys Glu Ile Gln Gly
 65 70 75 80

Leu His Gly Ile Cys Met Thr Phe Leu His Asn Ala Gly Lys Phe Asp
 85 90 95

Ala Gln Gly Lys Ser Phe Ile Lys Asp Ala Leu Arg Cys Lys Ala His
 100 105 110

Ala Leu Arg His Lys Phe Gly Cys Ile Ser Arg Lys Cys Pro Ala Ile
 115 120 125

Arg Glu Met Val Phe Gln Leu Gln Arg Glu Cys Tyr Leu Lys His Asp
 130 135 140

Leu Cys Ser Ala Ala Gln Glu Asn Val Gly Val Ile Val Glu Met Ile
 145 150 155 160

His Phe Lys Asp Leu Leu Leu His Glu Pro Tyr Val Asp Leu Val Asn
 165 170 175

Leu Leu Leu Thr Cys Gly Glu Asp Val Lys Glu Ala Val Thr Arg Ser
 180 185 190

Val Gln Ala Gln Cys Glu Gln Ser Trp Gly Gly Leu Cys Ser Ile Leu
 195 200 205

Ser Phe Cys Thr Ser Asn Ile Gln Arg Pro Pro Thr Ala Ala Pro Glu
 210 215 220

His Gln Pro Leu Ala Asp Arg Ala Gln Leu Ser Arg Pro His His Arg
 225 230 235 240

Asp Thr Asp His His Leu Thr Ala Asn Arg Gly Ala Lys Gly Glu Arg

245

250

255

Gly Ser Lys Ser His Pro Asn Ala His Ala Arg Gly Arg Thr Gly Gly
 260 265 270

Gln Ser Ala Gln Gly Pro Ser Gly Ser Ser Glu Trp Glu Asp Glu Gln
 275 280 285

Ser Glu Tyr Ser Asp Ile Arg Arg
 290 295

<210> 9
 <211> 26
 <212> PRT
 <213> Artificial

<220>
 <223> Mouse Stanniocalcin-1 forward primer

<400> 9

Gly Ala Ala Cys Cys Ala Gly Ala Ala Ala Ala Gly Cys Thr Ala Gly
 1 5 10 15

Thr Cys Ala Ala Gly Thr Gly Thr Gly Thr
 20 25

<210> 10
 <211> 29
 <212> DNA
 <213> Artificial

<220>
 <223> Mouse Stanniocalcin-1 reverse primer

<400> 10
 gagaaaagag aaagaaagtt tactgaact 29

<210> 11
 <211> 34
 <212> DNA
 <213> Artificial

<220>
 <223> Mouse Stanniocalcin-1 probe

<400> 11
 cagaagccca aagtggcaaa tagcttatga gaat 34

<210> 12
 <211> 22
 <212> DNA
 <213> Artificial

<220>
 <223> Mouse Stanniocalcin-2 forward primer

<400> 12
 gttgtattga atcggccgtg ta 22

<210> 13
 <211> 22
 <212> DNA
 <213> Artificial
 <220>
 <223> Mouse Stanniocalcin-2 reverse primer
 <400> 13
 ccccccaaca gaccatactt aa 22

<210> 14
 <211> 29
 <212> DNA
 <213> Artificial
 <220>
 <223> Mouse Stanniocalcin-2 probe
 <400> 14
 ctgtcttcgg tctgtggagt tagttggtg 29

<210> 15
 <211> 26
 <212> DNA
 <213> Artificial
 <220>
 <223> Mouse beta2-microglobulin forward primer
 <400> 15
 ccgaacatac tgaactgcta cgtaac 26

<210> 16
 <211> 21
 <212> DNA
 <213> Artificial
 <220>
 <223> Mouse beta2-microglobulin reverse primer
 <400> 16
 tttcccgttc ttcagcattt g 21

<210> 17
 <211> 26
 <212> DNA
 <213> Artificial
 <220>
 <223> Mouse beta2-microglobulin probe
 <400> 17
 cagttccacc cgctcacat tgaat 26

<210> 18
 <211> 23
 <212> DNA
 <213> Artificial
 <220>
 <223> stanniocalcin forward primer

<400> 18
tgaagacaca gtcagcacia tca

23

<210> 19
<211> 19
<212> DNA
<213> Artificial

<220>
<223> stanniocalcin reverse primer

<400> 19
ggaagaggct ggccatggt

19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/41882

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(7) : C12Q 1/68
 US CL : 435/6, 7.1
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 435/6, 7.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 BRS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | WO 93/00588 (THE BIOMEMBRANE INSTITUTE) 07 January 1993 (07.01.1993), page 3, lines 6-25. | 1, 6 and 10 |
| X | WO 98/14206 (THOMAS JEFFERSON UNIVERSITY), 09 April 1998 (09.04.1998), page 4, lines 14-24. | 1 |
| X | US 5,994,103 A(OLSEN et al.) 30 November 1999 (30.11.1999), Figure 1A and column 11, lines 54-62. | 19-26 |

Further documents are listed in the continuation of Box C. See patent family annex.

| | | |
|---|-----|--|
| * Special categories of cited documents: | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" earlier application or patent published on or after the international filing date | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" | document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | | |
| "P" document published prior to the international filing date but later than the priority date claimed | | |

Date of the actual completion of the international search: 28 April 2005 (28.04.2005)
 Date of mailing of the international search report: 16 MAY 2005

Name and mailing address of the ISA/US: Mail Stop PCT, Attn: ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, Facsimile No. (703)305-3230
 Authorized officer: James S. Ketter (with signature), Telephone No. (703) 308-0196